Clinical Study Report Appendix 16.1.1  AstraZeneca  
Breztri PT010  - D5985C00007  
CONFIDENTIAL AND PROPRIETARY  1 of 2  
  Clinical Study Report Appendix 16.1.1  
 Drug Substance  Breztri PT010  
 Study Code  D5985C00007  
   
   
   
   
   
   
 
 
Appendix 16.1.1  
Protocol and Protocol Amendments  
 
 
 
Clinical Study Report Appendix 16.1.1  AstraZeneca  
Breztri PT010  - D5985C00007  
CONFIDENTIAL AND PROPRIETARY  2 of 2  
 VERSION OF PROTOCOL OR PROTOCOL AMENDMENT  
Global Document Name  Version No  Version Date  
First final version of the protocol prior to any amendments  1.0 08 December 2022  
 
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 1of 78 Doc ID: TMP -0010225
Template Version Number 7.0Clinical Study Protocol 
Study 
InterventionBreztri PT010
Study Code D5985C00007
Version 1.0
Date 08Dec 2022
A Randomized, Double -blind, Single Dose, 2 -way Crossover Study 
to Assess Bronchospasm Potentially Induced by the 
Hydrofluoroolefin (HFO) Metered Dose Inhaler (MDI) Propellant 
as Compared with the Hydrofluoroalkane (HFA) MDI Propellant 
in Participants with Asthma, W ell Controlled or Partially 
Controlled on Short -acting beta 2-agon ists (SABA) with or without 
Low -Dose Inhaled Corticosteroids (ICS) 
A multicenter, 2 -way crossover, phase IIIb, double -blind study  to assess bronchospasm 
potenti ally induced by HFO M DI as com pared wi th HFA MDI in participants with asthma, well 
controlled or partially controlled, on SABA  with or wi thout low-dose ICS
Sponsor  Name: AstraZeneca AB
Legal Register ed Address: AstraZeneca AB, 151 85 Södertälje, Sweden
Manufacturer: AstraZeneca AB, 151 85 Södertälje, Sweden
Regulatory Agency Identifier  Number(s)
Registry ID
IND 118313
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 3of 78 Doc ID: TMP -0010225
Template Version Number 7.0TABLE OF CONTENTS
TABLE OF CONTENTS ...................................................................................................... 3
LIST OF ABBREVIA TION S................................................................................................ 7
1 PROTOCOL  SUMMAR Y.................................................................................. 9
1.1 Synopsis ............................................................................................................. 9
1.2 Schema ............................................................................................................. 14
1.3 Schedule of Act ivities....................................................................................... 15
2 INTRODUCTION ............................................................................................ 17
2.1 Study  Rati onale ................................................................................................ 17
2.2 Background ...................................................................................................... 17
2.3 Benefit/Ri sk Assessment ................................................................................... 19
2.3.1 Risk Assessment ............................................................................................... 19
2.3.2 Hydrofluorool efin............................................................................................. 20
2.3.3 Risk Assessment for COVID- 19 Pandemic ....................................................... 20
2.3.4 Benefit Assessment ........................................................................................... 21
2.3.5 Overall Benefit/Risk Conclusio n....................................................................... 21
3 OBJECTIVES AND ENDPO INTS ................................................................... 22
4 STUDY  DESIGN ............................................................................................. 23
4.1 Overall De sign.................................................................................................. 23
4.2 Scientific Rationale for Study  Design ............................................................... 24
4.2.1 Parti cipant and Si te Input Into Desi gn............................................................... 25
4.3 Justification for Dose ........................................................................................ 25
4.4 End-of-study  Definit ion.................................................................................... 25
5 STUDY  POPULA TION .................................................................................... 26
5.1 Inclus ion Cri teria.............................................................................................. 26
5.2 Exclusio n Cri teria............................................................................................. 28
5.3 Lifest yle Considerat ions................................................................................... 29
5.3.1 Caffeine, Alcohol, and T obacco ......................................................................... 29
5.3.2 Activity............................................................................................................. 30
5.4 Screen Failures ................................
................................................................. 30
5.5 Criteria for T emporarily Delaying Enrolment/Randomisat ion/Administrati on of 
Study  Intervent ion............................................................................................ 31
6 STUDY  INTER VENTIONS AND CONCOMIT ANT THER APY ..................... 31
6.1 Study  Intervent ion(s) Administered ................................................................... 31
6.1.1 Medical Devices Including Co mbinat ion Products with a Device Const ituent...32
6.2 Preparati on, Handling, Storage, an d Accountabilit y.......................................... 32
6.3 Assignment to Study  Intervent ion..................................................................... 33
6.4 Blinding ............................................................................................................ 33
Clinical Study Pro tocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 4of 78 Doc ID: TMP -0010225
Template Version Number 7.06.5 Study  Interv ention Compliance ......................................................................... 34
6.6 Dose Modificat ion............................................................................................ 34
6.6.1 Retreatment Criteria .......................................................................................... 34
6.7 Continued Access to Study Intervent ion Aft er the End of the Study .................. 35
6.8 Treatment of Overdose ...................................................................................... 35
6.9 Prior and Concomi tant Therapy ........................................................................ 35
6.9.1 Prior Medi cations............................................................................................. 35
6.9.2 Concomitant Medications ................................................................................. 36
6.9.2.1 Vaccinat ions...................................................................................................... 37
6.9.3 Prohibited Medications ..................................................................................... 37
6.10 Discontinuati on of S tudy I ntervent ion and Partici pant 
Discontinuati on/W ithdrawal .............................................................................. 39
6.11 Discontinuati on of  Study  Intervent ion............................................................... 39
6.12 Parti cipant Discontin uation/W ithdrawal fro m the Study .................................... 39
6.13 Lost to Follow -up............................................................................................. 40
7 STUDY  ASSESSMENTS AND PROCEDURES .............................................. 41
7.1 Administrative and General/Baseline Procedures .............................................. 41
7.1.1 Dem ographics and Medical/Surgical History .................................................... 41
7.1.2 Height and W eight ............................................................................................ 42
7.1.3 Physical Examinat ions...................................................................................... 42
7.1.4 Vital Signs ........................................................................................................ 42
7.1.5 Electrocardiograms ........................................................................................... 42
7.1.6 Clinical Laboratory  Tests.................................................................................. 43
7.2 Efficacy Assessments ........................................................................................ 43
7.3 Safety Assessments ........................................................................................... 43
7.3.1 Asthma Control Quest ionnaire 5 ....................................................................... 43
7.3.2 Spirometry........................................................................................................ 44
7.3.2.1 Moni toring for Bronchospasm .......................................................................... 45
7.3.3 Other Safet y Assessments ................................................................................. 45
7.3.3.1 Pregnancy testing .............................................................................................. 45
7.4 AEs, SAEs, and Other Safet y Reporting ............................................................ 45
7.4.1 Time Period and Frequency for Collect ing AE and SAE Informat ion................ 46
7.4.2 Follow-up of  AEs and SAEs ............................................................................. 47
7.4.3 Causalit y Collection.......................................................................................... 47
7.4.4 AEs Based on Examinat ions and T ests.............................................................. 47
7.4.5 AEs Based on Signs and Symptoms .................................................................. 48
7.4.6 Adverse Events of Special Interest .................................................................... 48
7.4.7 Reporting of SAEs ............................................................................................ 49
7.4.8 Pregnancy ......................................................................................................... 50
7.4.8.1 Maternal Exposure ............................................................................................ 50
7.4.8.2 Paternal  Exposure ............................................................................................. 50
7.4.9 Medicat ion Error , Drug Abuse, and Drug Misuse .............................................. 51
7.4.9.1 Timelines .......................................................................................................... 51
Clinical Study Protocol - 1.0 AstraZeneca
Breztri PT010 - D5985C00007
CONFIDENTIAL AND PROPRIETARY 5 of 78 Doc ID: TMP-0010225
Template Version Number 7.07.4.9.2 Medication Error ............................................................................................... 51
7.4.9.3 Drug Abus e....................................................................................................... 51
7.4.9.4 Drug Misu se ..................................................................................................... 51
7.4.10 Reporting of Ov erdose ...................................................................................... 51
7.4.11 Medical Dev ice Deficiencies ............................................................................. 52
7.4.11.1 Time Period for Detecting Medical Device Deficiencies ................................... 52
7.4.11.2 Follow-up of Med ical Device De ficiencies ....................................................... 53
7.4.11.3 Prompt Reporting of Medical De vice Deficiencies to Spons or .......................... 53
7.4.11.4 Regulatory Reporting Requir ements for Device Deficien cies............................ 53
7.5 Pharmacokinetics.............................................................................................. 537.6 Pharmacodynamics ........................................................................................... 53
7.7 Optional Genomics Initiativ e ............................................................................ 53
7.8 Biomarkers ....................................................................................................... 547.9 Immunogenicity Assessments ........................................................................... 54
7.10 Health Economics OR Medical Resource Utilisation and Health Econo mics ..... 54
7.11 Study Participant Fee dback Questionnaire ........................................................ 54
8 STA TISTICAL C ONSIDERA TI ONS................................................................ 54
8.1 Statistical Hypotheses ....................................................................................... 54
8.2 Sample Size Deter mination ............................................................................... 54
8.3 Populations fo r Analyses................................................................................... 55
8.4 Statistical Analyses ........................................................................................... 55
8.4.1 General Considerations ..................................................................................... 55
8.4.1.1 Intercurrent Events ............................................................................................ 56
8.4.1.2 Strategy for Interc urrent Even ts ........................................................................ 56
8.4.2 Safety ............................................................................................................... 56
8.4.2.1 Primary Endpoint .............................................................................................. 56
8.4.2.2 Secondary Endpoints ........................................................................................ 57
8.4.3 Other Analy ses.................................................................................................. 58
8.4.3.1 Physical Examinations ...................................................................................... 58
8.4.3.2 Vital Signs ........................................................................................................ 58
8.4.3.3 Electrocardi ogram ............................................................................................. 58
8.5 Interim Analyses............................................................................................... 588.6 Data Monitoring/ Other Co mmittee .................................................................... 58
9 SUPPORTING DOCUMENTA TION AND OPERA TI ONAL
CONSIDERA TI ONS ........................................................................................ 58
10 REFERENCES................................................................................................. 78
LIST OF FIGURES
Figure 1 Study Design ........................................................................................... 14CCI
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 6of 78 Doc ID: TMP -0010225
Template Version Number 7.0LIST OF TABLES
Table 1 Schedule of Act ivities.............................................................................. 15
Table 2 Risk Assessment ...................................................................................... 19
Table 3 Object ives and Endpo ints......................................................................... 22
Table 4 Low Daily Metered Dose of ICS (Monotherapy  or in Combinati on wi th 
LABA) .................................................................................................... 36
Table 5 Allowed Medications with Defined Stable Dosing Period Prior to Visit 1 36
Table 6 Prohibited Medications Throughout the Study  and Pri or to Vi sit 1........... 37
Table 7 Prohibited Asthma and Allergy Medications During the Study  Conduct 
and Required Washout Period Prior to Visit 2 .......................................... 38
Table 8 Laboratory  Variables ............................................................................... 43
Table 9 Popul ations for Analysis .......................................................................... 55
LIST OF APPENDICES
Appendix A Regulatory , Ethical, and Study  Oversight Consi derati ons......................... 59
Appendix B AEs: Definit ions and Procedures for Recording, Evaluat ing, Fo llow-up, 
and Reporting .......................................................................................... 65
Appendix C Handling of Human Bio logical  Samples .................................................. 71
Appendix D Medical Device AEs, ADEs, SAEs, SADEs, USADEs, and Medical 
Device Deficiencies: Definit ions and Procedures for Recording, 
Evaluat ing, Follow -up, and Reporting ...................................................... 73
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 7of 78 Doc ID: TMP -0010225
Template Version Number 7.0LIST OF ABBREVIATION S 
Abbreviation or special 
termExplanation
ACQ Asthma Control Questionnaire
ADE Adverse device effect
AE Adverse event
AUC Area under the curve
AUC 0-15 min Area under the curve from 0 to 15 minutes
BGF Budesonide, glycopyrronium, and formoterol fumarate
CFR Code of Federal Regulations
CI Confidence interval
COPD Chro nic obstructive pulmonary disease
COVID -19 Coronavirus disease 2019
CRO Contract research organisation
CSR Clinical study report
DPI Dry powder inhaler
ECG Electrocardiogram
eCRF Electronic case report form
EDC Electronic data capture
EU European Union
FEV 1 Forced expiratory volume in 1 second
GCP Good Clinical Practice
GINA Global Initiative for Asthma
GWP Global warming potential
HBS Human biological sample(s)
HFA Hydrofluoroalkane
HFO Hydrofluoroolefin
IATA International Air Transport Association
IB Investigator’s Brochure
ICE Intercurrent event
ICF Informed consent form
ICH International Council for Harmonisation
ICS Inhaled corticosteroid
IMP Investigational medicinal product
IND Investigational New Drug
IRB Institutio nal review board
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 8of 78 Doc ID: TMP -0010225
Template Version Number 7.0Abbreviation or special 
termExplanation
IRT Interactive Response Technology
LABA Long -acting beta 2-agonist
MDI Metered dose inhaler
NI Non-inferiority
NIMP Non-investigational medicinal product 
RTSM Randomisation and Trial Supply Management
SADE Serious adverse device effect
SAE Serious adverse event 
SABA Short -acting beta 2-agonists
SAP Statistical Analysis Plan
SoA Schedule of activities
USADE Unanticipated serious adverse device effect
Clinical Study Protocol - 1.0 AstraZeneca
Breztri PT010 - D5985C00007
CONFIDENTIAL AND PROPRIETARY 11 of 78 Doc ID: TMP-0010225
Template Version Number 7.0needed (not approved in the US), or SABA as needed, or low-dose ICS whenever SABA as 
needed is used, through the study. 
 
 
 
 
 
 
 
 
  
 
 
Brief Summary:
The purpose of this study is to assess bronchospasm potentially induced by hydrofluoroolefin 
(HFO) metered dose inhaler (MDI) as compared with hydrofluoroalkane (HFA) MDI inparticipants with asthma, well controlled or partially controlled on treatment for asthma, including, low-dose inhaled corticosteroid (ICS) daily or low-dose ICS/formoterol as needed 
(not approved in the US ), or short-acting beta
2-agonists (SABA) as needed, or low-dose ICS 
whenever SABA as needed is used .  
Study details include:
!
Disclosure Statement: This is a 2-way crossover study with 2 treatment arms that is 
participant, sponsor, and investigator blinded.
Number of Participants:
It is estimated that approximately 52 participants with well controlled or partially controlled 
asthma will be randomized to achieve 46 completers, with 26 participants in each treatment CCICCI
Clinical Study Protocol - 1.0 AstraZeneca
Breztri PT010 - D5985C00007
CONFIDENTIAL AND PROPRIETARY 12 of 78 Doc ID: TMP-0010225
Template Version Number 7.0sequence. This assumes a 10% dropout rate.
Study Arms and Duration:
 
 
Study treatment will be administered via MDI device as 4 inhalations:
!Treatment A: HFO propellant only MDI; 4 inhalations per dose – test formulation
!Treatment B: HFA propellant only MDI; 4 inhalations per dose – reference 
formulation
Participants will be randomized in a ratio of 1:1 to receive treatments in one of two possible 
treatment sequences: A followed by B, or B followed by A. 
Data Monitoring/Other Committee: No
Statistical Methods
The null hypothesis tested in this study for the primary objective is that HFO MDI (test arm) 
is inferior to HFA MDI (reference arm) in terms of the change from baseline in FEV 1AUC 0-15 
min, versus the alternative hypothesis that the test arm is non-inferior to the reference arm. The 
non-inferiority (NI) margin is  set at – 200 mL.  If the lower limit of the 2-sided 95% 
confidence interval (CI) for the difference in the mean change from baseline of HFO MDI minus HFA MDI  is > −200 mL, then NI will be demonstrated. 
 
 
 
 
.
The following populations are defined:CCI
CCI
CCI
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 13of 78 Doc ID: TMP -0010225
Template Version Number 7.0Population/Analysis set Description
Enrolled All participants who sign the ICF . The Enrolled Analysis Set will be used to 
summarise disposition.
Randomised All enrolled participants who are randomised to one of the study treatment 
sequences. The Randomised Analysis Set will be used to summarise 
baseline characteristics.
Safety All participants who are randomised to one of the study treatment sequences 
and have received any amount of the study treatment (ie, at least 1 puff). 
Participants will be analysed according to the actual treatment received. 
Abbreviations: ICF = informed consent form.
For secondary  safety  endpoints and other safet y assesssments, no formal statist ical analyses 
will be performed. Descriptive summaries will be produced and any  clinically  relevant 
differences will be noted and discussed.
Dem ographic and baseline characterist ics data will be summarised by treatment sequence. 
Categorical variables will be summarised using frequency and percentages, where the 
deno minator for calculat ion is the underlying analysis set populat ion unless otherwise 
specified . Continuous vari ables will be summarised with descript ive statist ics using number of 
available observat ions, mean, standard deviat ion, median, minimum, and maximum, and 
quartiles where appropriate.
The primary  endpoint is defined as change from baseline i n FEV 1 AUC 0-15 min post-dose. The 
analysis will be performed based on the Safet y Analysis Set using a Principal Stratum 
estimand .
Change in FEV 1AUC 0-15 min post-dose will be calculated fro m FEV 1change fro m baseline at 
5and 15 minutes post -dose using the trapezoidal rule, divided by the actual observat ion time 
from the first to the l ast non -missing value, for each treatment period. Baseline is the FEV 1
value obtained within 30 minutes prior to s tudy intervent ion administration in each treatment 
period.
For the primary  endpoint, a Mixed Model Repeated Measures analysis wit h treatment
sequence, period, average baseline FEV 1, and treatment as fixed effects, and participant within 
sequence as the ran dom effect will be used. Average baseline (period -specific baseline FEV 1
averaged over the treatment periods) is included to account for cross -level bias.
Adjusted m ean change fro m baseline est imates per treatment group and corresponding 2 -sided 
95% CIs al ong wi th an overall estimate of the treatment difference (HFO MDI minus HF A 
MDI) will be presented. If the lower limit of the 2 -sided 95% CI for the difference in mean 
change from baseline o f HFO MDI minus HF A MDI is > −200 mL, the null hypothesis of 
Clinical Study Protocol - 1.0 AstraZeneca
Breztri PT010 - D5985C00007
CONFIDENTIAL AND PROPRIETARY 15 of 78 Doc ID: TMP-0010225
Template Version Number 7.01.3 Schedule of Activities
Table 1 Schedule of Activities
Details in protocol section or 
appendix
Informed consentdX Section  5.1
Inclusion/exclusion criteria X X Sections  5.1and 5.2
Verify continued eligibility X X Sections  5.1and 5.2
ACQ-5 XeSection  7.3.1
Randomisation X Section  6.3
Routine clinical procedures
Demographics and medical/surgical 
historyXSections  5.1, 5.2, and 7.1.1
Prior/concomitant medication review X X X X X X Section  6.9
SpirometryfXX  gX gX X Section  7.3.2
Routine safety measurements
AE X X X X X XSection  7.4and
Appendix B
Pregnancy testinghXX XSections  5.1
and 7.3.3.1
FSH hX Section  7.3.3.1
(Local) Clinical laboratory tests (blood and 
urine)XSection  7.1.6
Physical examination X X iX iX Section  7.1.3CCI
Clinical Study Protocol - 1.0 AstraZeneca
Breztri PT010 - D5985C00007
CONFIDENTIAL AND PROPRIETARY 16 of 78 Doc ID: TMP-0010225
Template Version Number 7.0Table 1 Schedule of Activities
Details in protocol section or 
appendix
Height and weight X Section  7.1.2
Vital signs X XiXiX Section  7.1.4
12-lead ECG X Section  7.1.5
Study intervention administration
Inhalation technique verification X X X Section  6
Administer blinded study intervention in 
clinicXXSections  4.1and 6
aAll participants should remain on their current treatment for asthma through the study, including, low-dose ICS daily or low-do se ICS/formoterol as needed (not approved in 
the US), or SABA as needed, or low-dose ICS whenever SABA as needed is used.
bAssessments done at unscheduled visits are at the discretion of the Investigator.
c sites should call participants 1 to 2 days before each schedu led in-clinic visit to remind them of the upcoming visit and relat ed 
restrictions/requirements, including withholding morning dose of asthma medications on the day of on-site study visit.
dICF could be signed up to 7 days prior to  
eWhether the participant has an ACQ-5 score < 1.5 and a pre-dose FEV 1> 60% will be assessed at  for study participation.
fAlbuterol/salbutamol must be withheld for at least 8 hours prior to FEV 1 measurements. All LABAs, formoterol included and combinations there-of, must be withheld for 48 
hours prior to spirometry.
gPre-dose spirometry will be performed at 30 minutes prior to dosing and post-dose spirometry will be performed at 5, 15, and 30  minutes after dosing. During both Treatment 
Periods, if FEV 1 drops > 15% from baseline, measurements should be repeated at Investigator’s discr etion until FEV 1 values are within 10% of baseline performed that day.
hA serum pregnancy test  and urine pregnancy tests at following visits will be performed for women of childbearing potential. A serum FSH test will be conducted at 
only, for women who have been amenorrhoeic for 12 months without an alternative medical cause, to confirm postmenopausal status .
iAssessments will be performed prior to dosing. Brief physical examinations will be performed at  
Abbreviations: ACQ-5 = Asthma Control Questionnaire 5; AE = adverse event; ECG = electrocardiogram; FEV 1 = forced expiratory volume in 1 second; FSH = follicle-
stimulating hormone; ICF = informed consent form; ICS = inhaled corticosteroid;  LABA = long-acting beta 2-agonist; TC = telephone c ontact; WD = withdrawal.CCI
CCI
CCI
CCI
CCICCI
CCI
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 17of 78 Doc ID: TMP -0010225
Template Version Number 7.02 INTRODUCTION
The sponsor, AstraZeneca, has developed orally inhaled drug products containing budesonide 
(an inhaled corticosteroid; ICS), glycopy rroni um (a long-acting muscarinic a ntagoni st), and 
formoterol  fumarate (a long-acting beta 2-agoni st)(BGF metered dose inhaler [MDI]) for the 
treatm ent of asthma. These drug products are formulated as a suspensio n with microni zed 
active pharmaceut ical ingredients and Co -Suspension ™ Delivery Techno logy in MDIs. The 
Co-Suspensio n Delivery T echno logy of spray -dried porous parti cles co mprised of the 
phospho lipid 1,2 -distearoyl -sn-glycero -
3-phosphocho line and calcium chloride suspended in a 
hydrofluoroalkane (HF A) propellant. Hy drofluorool efin (H FO) has been ident ified by sponsor 
as a novel propellant potentially suitable for replacement of HF A
-134a in the BGF MDI HF A 
product for the purpose of lowering global warming potential  (GWP).
The test and reference formulat ion used in this study  is an MDI with a desi ccated fl ow path 
containing HF A or HFO propellant only .
2.1 Study Rationale
The current HFA (HFA -134a) propellant in AstraZeneca’s MDI ty pe treatm ents is known to 
have a relat ively high GWP co mpared to some new alternative propellants, and contribu tes 
substant ially to AstraZeneca’s carbon footprint. In order to address this issue, AstraZeneca is 
evaluat ing an MDI reformulated with a next generation propellant HFO ( HFO -1234ze) , which 
has a near zero GWP and will allow pat ients to cont inue to use MDI type treatm ents, while 
contributing to AstraZeneca’s sustainabilit y efforts. 
As part of the clinical development program for gaining regulatory  approval  for BGF MDI 
HFO for the treatment of asthma and chronic obstructive pulmo nary disease (COPD), and for 
supporting other potential products, this study  is being conducted to assess if HFO MDI 
induces a potential change in FEV 1as com pared to HFA MDI in participants with well 
controlled or partially controlled asthma, as primarily  evaluated by  change from  baseline in 
forced expiratory  volume in 1 second (FEV 1)area under curve fro m 0 to 15 minutes (AUC 0-15 
min) post -dose .
2.2 Background
Asthma i s a heterogeneous disease that is characterized by  chronic ai rway  inflammat ion and 
bronchial hyperreact ivity. It is defined by  a history of respiratory  symptom s such as wheeze, 
shortness of breath, chest tightness, and cough that vary  over time and in intensit y, together 
with variable expiratory  airfl ow obstructi on [Global Initiative for Asth ma (GINA) Guidance
2022].
The l ong-term goal s of asthma m anagement are risk reduction and symptom control. The aim 
is to reduce the patient burden and risk of asthma -related death, exacerbations, airway  
damage, and m edicat ion side effects. The patient ’s ow n goals regarding their asthma and its 
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT 010-D5985C00007
CONFIDENTIAL AND PROPRIETARY 18of 78 Doc ID: TMP -0010225
Template Version Number 7.0treatm ent shoul d also be i dentified [ GINA  2022 ]. This concept enco mpasses 2 components: 
(1) pati ent’s recent clinical status and current disease impact which includes assessment of 
symptoms , night awakenings, use of rescue medication, and lung funct ion and (2) patient 
assessment for future risk of exacerbations, decline in lung funct ion, or treatment -related side 
effects. 
AstraZeneca has developed MDI products with HF A for the treatm ent of asthma. Their 
formulations are generally co mprised of a therapeutic material, a propellant, co- solvents, and 
surfactants. The HF A MDI products are formulated with HF A-134a propellant, a liquefied 
compressed gas, in which the active pharmaceut ical ingredien ts are suspended. HF A-134a is a 
commo n propellant in pharmaceut ical MDI products that provides the force to generate an 
aerosol to deliver a product inhalation or dose. More information on the HF A MDI drug 
product is provided in the BGF MDI Invest igator ’s Brochure (IB). 
The current HF A (HFA-134a) propellant in AstraZeneca ’s MDI ty pe treatm ents is known to 
have a relat ively high GWP co mpared to some alternat ive propellants, and contributes 
substant ially to AstraZeneca ’s carbon footprin t. HFO -1234ze, which is available for industrial 
uses such as refrigerat ion, has been further purified by the manufacturer through fract ional 
distillation to provide a propellant of suitable grade for clinical studies. HFO -1234ze has a 
near-zero GWP and ve ry low photochemical  react ivity. In addi tion, it has very  similar physical 
properties to HF A-134a, which are expected to have comparable performance of the HF A 
MDI product. The sponsor has ident ified HFO -1234ze as a novel propellant potentially 
suitable fo r repl acement of HF A-134a in the BGF MDI HF A product. 
Study  D5985C00001 assessed the safet y and tol erabili ty of a combinat ion of BGF when 
administered as single doses in 3 different propellant formulations: BGF MDI HFO, BGF 
MDI hydrofluorocarbon, and BGF MDI HF A in 47 healt hy vo lunteers. The combinat ion of 
BGF when administered as single doses in 3 different propellant formulat ions demo nstrated a 
similar and acceptable safet y profile amo ng 3 formulat ions and was well tolerated in healt hy 
volunteers. The de velopment of BGF MDI HFO products including non -clinical toxicology  
resul ts and study  D5985C00001 results is specified in IBSecti on 3.2.3, Secti on 5.2.5, and 
Appendix A.
To further support HFO -1234ze regulatory applications, this stu dy will assess the safet y and 
tolerabilit y of HFO -1234ze (HFO MDI; propellant only) co mpared with HF A-134a (HF A 
MDI; propellant only ) delivered in parti cipants wi th well  controlled or parti ally controlled on 
treatm ent for asthma, including, low -dose ICS da ily or low -dose ICS/formoterol as needed 
(not approved in the US), or short -acting beta 2-agonists (SABA) as needed, or low -dose ICS 
whenever SABA  as needed is used , defined as an Asthma Control Quest ionnaire 5 (ACQ -5) 
score < 1.5. 
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 19of 78 Doc ID: TMP -0010225
Template Version Number 7.02.3 Benefit/Risk Assessment
More detailed informat ion about the known and expected benefits and potential risks of HFO 
MDI and HF A MDI m ay be found in the IB.
2.3.1 Risk Assessment
Table 2 Risk Assessment
Potential risk of clinical 
significanceSummary of data/rationale for 
risk Mitigation strategy
Study intervention
Safety (ie, risk of bronchospasm) Study intervention is a pMDI 
containing HFA or HFO 
propellant only.Participants will be well controlled 
or partially controlled on 
treatments for asthma, including,  
low-dose ICS daily  or low-dose 
ICS/formoterol as needed (not 
approved in the US), or SABA as 
needed, o r low-dose ICS whenever 
SABA as needed is used .
Study procedures
Risk of bronchospasm Handling of bronchospasm events
by site staff in case such event 
happensSites will be equipped with well 
trained site staff to deal with 
bronchospasm events. Sites will 
also provide appropriate 
medications for bronchospasm 
treatment. 
In the event of a bronchospasm, 
participants could be discharged 
should FEV 1values be within 10% 
of the baseline FEV 1performed 
that day, or at investigator 
discretio n.
Trial integrity Improper blinding leading to bias Participants should not be able to 
distinguish the propellants by 
colour or smell since they are 
similar. There are few participants 
and o nly 2 products that need to be 
blinded.
Study population
Safety 1. Asthma stability is related to 
seasonality.
2. Excessive hyperreactivity may 
happen because some patients that 
are perceived as having mild 1. For inclusion criteria, 
participants with asthma ACQ -5 
score < 1.5 will be enrolled, which 
is also an indication of the stability 
of asthma.
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 21of 78 Doc ID: TMP -0010225
Template Version Number 7.0Parti cipants will be cl osely m onitored f or any  signs and symptom s of COVID -19, 
including fever, dry  cough, dyspnea, sore throat, and fat igue throughout the study . Once 
clinical signs o f infect ion are reported by  parti cipants, the invest igator needs to determine 
whether samples can be co llected, and safet y data can be recorded on site. If not, adverse 
events (AEs) and conco mitant m edicati ons will be obtained via phone calls. Daily  body 
temperature m easurements during outpatient visit s will be implemented.
The invest igator will not dose participants upon ident ificat ion of any signs of COVID -19 
infect ion.
The probabilit y of virus transmission will be controlled as much as possible by:
Advisin g the parti cipant to adhere to local requirements for reduction of the public 
exposure while ambulatory .
If applicable, all participants will be contacted by  phone 1 day  prior to every  visit for 
assessing COVID-19 symptoms and signs and are asked not to at tend the si te in case 
of suspected reports. In addit ion, parti cipants are asked for any  contact wi th a person 
who has tested posit ive for severe acute respiratory syndrome coronavirus 2. If 
applicable, participants will be referred to the local healt h care system  for further 
follow-up and treatment.
Physical distancing and person- to-person contact restrict ions will be applied during 
site visi ts.
Where physical distancing is not possible, personal protective equipment will be used 
by participants (surgical f ace m asks, gl oves) and staff (for example, but not limited to 
masks, gl oves, protectors, medical suits) if deemed appropriate by  the invest igator 
and site staff and guided by local requirements.
Logist ical improvements of the site and structural measures o f the study  site building 
will be implemented to further improve physical distancing.
2.3.4 Benefit Assess ment
No di rect benefit for individuals in this study  is expected. Indi rect benefit s include assist ing 
with clinical  devel opment of  MDI products with a lower GWP.
2.3.5 Overall Benefit/Risk Conclusion
Considering the measures taken to minimize risk to participants participat ing in this study , the 
potenti al risks i dentified in associat ion with HFO MDI are justified by  the ant icipated indirect 
benefits that may be aff orded wi th regard to a reduced carbon footprint of MDI products.
Clinical Study Protocol - 1.0 AstraZeneca
Breztri PT010 - D5985C00007
CONFIDENTIAL AND PROPRIETARY 23 of 78 Doc ID: TMP-0010225
Template Version Number 7.04 STUDY DESIGN
4.1 Overall Design
This is a phase 3b, multicentre, randomize d, double-blind, single-dose crossover study 
comparing the safety and tolerability of HFO MDI with HFA MDI delivered in participants 
with well controlled or partially controlled asthma defined as an ACQ-5 score < 1.5 .Eligible 
participants are at least 18 years of age and no older than 45 years of age and are required to 
have asthma as defined by GINA guidelines ( GINA 2022 ). Participants are required to be well 
controlled or partially controlled on their current treatment for asthma, including, low-doseICS daily or low-dose ICS/formoterol as needed (not approved in the US), or SABA as needed, or low-dose ICS whenever SABA as needed is used. The primary objective is to 
assess the potential change in FEV
1induced by HFO MDI as compared with HFA MDI in 
participants with asthma.
This study will be conducted at approximately 5 sites in the US and will rando mize 
approximately 52 adult participants to achieve 46 completers.
 
 
Single dose study treatment will be administered via MDI device as 4 inhalations:
!Treatment A: HFO propellant only MDI; 4 inhalations per dose – test formulation
!Treatment B: HFA propellant only MDI; 4 inhalations per dose – reference 
formulation
Participants will be randomized in a ratio of 1:1 to receive treatments in one of two possible 
treatment sequences: A followed by B, or B followed by A. 
All participants will remain on their current treatment for asthma, including, low-dose ICS 
daily or low-dose ICS/formoterol as needed (not approved in the US), or SABA as needed, or low-dose ICS whenever SABA as needed is used, during the screen ing, treatment, and 
washout periods.
Note: Albuterol/salbutamol must be wi thheld for at least 8 hours prior to FEV
1measurements.
 participants’ eligibility will be verified, and whether the participant has an ACQ-5 
score < 1.5 and a pre-dose FEV 1> 60% will be assessed. Participants will remain on their CCI
CCI
Clinical Study Protocol - 1.0 AstraZeneca
Breztri PT010 - D5985C00007
CONFIDENTIAL AND PROPRIETARY 24 of 78 Doc ID: TMP-0010225
Template Version Number 7.0current treatment for asthma, including, low- dose ICS daily or low-dose ICS/formoterol as 
needed (not approved in the US), or SABA as needed, or low-dose ICS whenever SABA as needed is used, through the study. 
 
 
 
 
 
 
 
 
 
 
Note: An event of bronchospasm is defined as a reduction in FEV 1of > 15% from baseline (ie, 
the FEV 1value obtained within 30 minutes prior to study intervention administration) at 5 or 
15 minutes post-dose with associated symptoms of wheezing, shortness of breath, or cough.
For details on study interventions given during the study, see Section  6.1. The study schematic 
with flow of events for all treatments, depending on the participant’s assigned randomization is presented in  Figure 1 . The schedule of activities (SoA) displaying assessments/tasks and 
timepoints is presented in  Table 1 .
4.2 Scientific Rationale for Study Design
The primary objective is to assess the potential change in FEV 1induced by HFO MDI as 
compared with HFA MDI in participants with  asthma. As such, the primary endpoint is the 
change from baseline in FEV 1 AUC 0-15 min post-dose. The secondary objectives of the study 
are to assess the potential of bronchospasm induced by HFO MDI as compared to HFA MDI 
in participants with asthma, measured as  the cumulative incidence of bronchospasm events, 
and to assess the safety and tolerability of HFO MDI as compared to HFA MDI in participants with asthma, evaluated in terms of AEs. An event of bronchospasm is defined as a reduction in FEV
1of > 15% from baseline (ie, the FEV 1value obtained within 30 minutes prior to study 
intervention administration) at 5 or 15 minutes post-dose.CCI
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 25of 78 Doc ID: TMP -0010225
Template Version Number 7.0The study  is double blinded to minimize any  bias from  the parti cipants, invest igators, or 
sponsor that may  affect study  resul ts. Parti cipants will be randomised to prevent bias in 
allocat ion of treatm ents in each treatm ent peri od, wi th each parti cipant serving as his/her own 
matched control.
This study  will enroll parti cipants wi th well  controlled or parti ally controlled asthma defined 
by ACQ -5 score < 1.5 who are on current treatment with low-dose ICS daily or low-dose
ICS/form oterol  as needed (not approved in the US), or SABA  as needed, or low-dose ICS 
whenever SABA  as needed is used . As pat ients with asthma have hyperreactive airways and 
could be m ore prone to develop a bronchospasm as compared with pat ients with COPD, 
asthma patients were chosen for this study  even though the MDI products are intended to be 
used in both populat ions. Parti cipants in the study  will be maintained on their current 
treatm ent, open -label, at study  entry .. Thi s woul d allow an effe ctive assessment of potential 
events of bronchospasm should they  be induced by HFO propellant in co mpar ison to the HF A 
propellant in the study . 
4.2.1 Participant and Site Input Into Design
Gathering input on study  design from  both investigators and aimed study popul ation has been 
part of the preparations for this study  and devel opment of this Clinical Study  Protocol . This 
aims to provide opportunit ies for informing study  design, improving operational aspects of the 
study , reducing patient/site burden and retaini ng interest, enthusiasm, and engagement in a 
study . Invest igator input has been provided by potent ial sites as part of the study  feasibili ty 
evaluat ion. Parti cipant input has been obtained from similar programs/studies where 
interviews have been held with asthma patients.
4.3 Justification for Dose
The dose of BGF MDI HF A is 2 inhalat ions per dose for a total of 4 inhalat ions per day . As 
there is no regulatory  or com pany precedent for dosing in this t ype of study , a single dose of 
4inhalations of HF A/HFO prope llant will be administered, which is the same dose as the 
maximum daily dose of propellant administered with BGF MDI HF A. This dose is well wit hin 
the safet y margin of the non -clinical exposure data.
4.4 End-of-study Definition
For the purpose of clinical tria l transparency , the definit ion of the end of the study  differs 
under FDA  and EU regul atory  requi rements:
European Unio nrequi rements define study  com pletion as the l ast vi sit of the l ast subject for 
any protocol -related activit y.
Food and Drug Administrati on requi rements defines 2 com pletion dates:
Clinical Study Protocol - 1.0 AstraZeneca
Breztri PT010 - D5985C00007
CONFIDENTIAL AND PROPRIETARY 26 of 78 Doc ID: TMP-0010225
Template Version Number 7.0Primary Completion Date – the date that the final participant is examined or receives an 
intervention for the purposes  of final co llection of d ata for the primary outcome measure, 
whether the clinical study concluded according to the pre-specified protocol or was terminated. In the case of clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed 
for all of the primary outcomes.
Study Completion Date – the date the final participant is examined or receives an intervention 
for purposes of final collection of data for th e primary and secondary outcome measures and 
AEs (for example, last participant’s last visit), whether the clinical study concludes according to the pre-specified protocol or is terminated.
A participant is considered to have completed the study if they have completed all phases of 
the study including the last scheduled treatment period shown in the SoA (Table 1 ).
5 STUDY POPULATION
Prospective approval of protocol deviations to recruitment and enrolment criteria, also known 
as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
Participants are eligible to be included in the study only if all of the following criteria apply:
Age
1 Male and female participant must be 18 to 45 years of age inclusive, at the time of 
signing the informed consent form (ICF).
Type of Participant and Disease Characteristics
2 Participants who have a documented history of physician-diagnosed asthma 
≥12 months prior to Visit 1, according to GINA guidelines ( GINA 2022 ).
3 Participants who are well controlled or partially controlled on their current treatment for 
asthma, including, low-dose ICS daily or low-dose ICS/formoterol as needed (not approved in the US), or SABA as needed, or low-dose ICS whenever SABA as neededis used (low-dose ICS as defined by  GINA 2022 inTable 4 ), for 4 weeks prior to 
screening.
4 ACQ-5 total score < 1.5 at 
5 A pre-bronchodilator FEV
1> 60% predicted normal value at 
6 Demonstrate acceptable MDI administration technique.CCI
CCI
Clinical Study Protocol - 1.0 AstraZeneca
Breztri PT010 - D5985C00007
CONFIDENTIAL AND PROPRIETARY 27 of 78 Doc ID: TMP-0010225
Template Version Number 7.0Sex and Contraceptive/Barrier Requirements
7 Females must be not of childbearing potential, or should be using a form of highly 
effective birth control as defined below: 
! Female participants: Women not of childbearing potential are defined as women 
who are either permanently sterilised (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postm enopausal. Women included in this 
study will be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatment and follicle-stimulating hormone levels  in the postmenopausal range. 
! Female participants of childbearing potential must use one highly effective form 
of birth control. A highly effective method of contraception is defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly. At enrolment, women of childbearing potential who are sexually active with a non-sterilised male partner should be stable on their chosen method of highly effective birth control, as defined below, and willing to remain on the birth control until at least 14 days after last dose of study intervention. Cessation of 
contraception after this point should be discussed with a responsible physician. 
Periodic abstinence (calendar, sy mptothermal, post-ovulation methods), 
withdrawal (coitus interruptus), spermicides only, and lactational amenorrhoea method are not acceptable methods of contraception. Female condom and male condom should not be  used together. All women of childbearing potential must 
have a negative serum pregnancy test result 
! Highly effective birth control methods are listed below:
oTotal sexual abstinence is an acceptable method provided it is the usual 
lifestyle of the participant (defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments). Periodic abstinence (e .g., calendar, ovulation, symptothermal, 
post-ovulation methods), declaration of abstinence for the duration of exposure to study intervention, and withdrawal are not acceptable methods 
of contraception.
oContraceptive subdermal implant
oIntrauterine device or intrauterine system
oOral contraceptive (combined or progesterone only)
oInjectable progestogen
oContraceptive vaginal ring
oPercutaneous contraceptive patches
oMale partner sterilisation with docum entation of azoospermia prior to the 
female participan t’s entry into the study, and this male is the sole partner for 
that participant. The documentation on male sterility can come from the site CCI
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 28of 78 Doc ID: TMP -0010225
Template Version Number 7.0personnel’s review of participant’s medical records, medical examinat ion 
and/or sem en analysis or medical history  interview provided by  her or her 
partner.
oBilateral tubal ligat ion
Informed Consent
8 Capable of giving signed informed consent as described in Appendix Awhich incl udes 
compliance wi th the requi rements and restri ctions listed in the ICF and in this protocol.
5.2 Exclusion Criteria 
Parti cipants are excl uded from  the study  if any of the fo llowing cr iteria apply:
Medical Conditions
1Life-threatening asthma defined as a history  of significant asthm a episode(s) requiring 
intubation associated with hypercapnia, respiratory arrest, hy poxic seizures, or asthma 
related syncopal  episode(s).
2Current sm okers, f ormer smokers wi th > 10 pack -years history , or f ormer sm okers who 
stopped smoking < 6 months prior to Visit 1 (including all forms o f tobacco, e -cigarettes 
or other vaping devices, and marijuana).
3Historical or current evidence o f a clinically  significant disease including, but not limited 
to: cardiovascular, hepat ic, renal, hematological, neurological, endocrine, gastrointestinal, 
or pulmo nary (e.g., active tuberculosis, bronchiectasis, pulmo nary eosinophilic 
syndro mes, COPD, and uncontrolled severe asthma ). Significant i s defined as any disease 
that, in the opinio n of the invest igator, would put the safet y of the parti cipant at ri sk 
through participat ion, or that could affect the safety/tolerabilit y analysis.
4Any respiratory  infecti on or asthma exacerbatio n treated wi th systemic corticosteroids 
and/or addit ional ICS treatment in the 8 weeks prior to Visit 1 and throughout the 
screening period.
5Hospitalization for asthma wit hin 1 year prior to Visit 1.
6Admissio n to i ntensive care unit or mechanical vent ilation due to asthm a exacerbat ion.
7Known history  of drug or al coho l abuse within 12 mo nths of Visit 1.
Prior/Concomitant Therapy
8Do not m eet the stabl e dosing peri od pri or to Visit 1 (see Table 5) or unable to abstain 
from protocol -
defined prohibited medications during screening and treatment periods (see 
Table 6and Table 7).
9Receipt of COVID -19 vaccine (regardless of vaccine delivery  platform, e.g., vector, lipid 
nanoparti cle) ≤ 7 day s prior to Vi sit 1 (f rom last vaccinat ion or booster dose).
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 29of 78 Doc ID: TMP -0010225
Template Version Number 7.0Prior/Concurrent Clinical Study Experience
10Parti cipation in another clinical study  with an investi gational product administered within 
30 day s or 5 half-lives (whichever is longer).
11Parti cipants wi th a known hypersensit ivity to HFO or HFA or any  of the excipients of the 
product.
12Previously  randomised into a study  with an HFO -containing MDI.
Diagnostic Assessments
13Any clinically  relevant abnorm al find ings in physical examinat ion, clinical chemistry , 
hematol ogy, urinalysis, vital signs, or electrocardiogram (ECG), which in the opinio n of 
the invest igator, may put the participant at risk because of his/her participat ion in the 
study .
Note: Participants with ECG QT interval corrected for heart rate using Fridericia’s 
formula (QTcF) > 480 msec will be excluded. Participants with high degree 
atrioventri cular bl ock II or III, or with sinus node dy sfunct ion with clinically  significant 
pauses who are not treat ed with pacemaker will also be excluded. 
Other Exclusions
14Involvement in the planning and/or conduct of the study (applies to both AstraZeneca 
staff and/or staff at the study  site).
15Judgment by  the invest igator that the participant should not participate in the study if the 
participant is unlikely  to com ply with study  procedures, restrict ions, and requirements.
16Previous enrolment or randomisat ion in the present study . 
17For wom en only –current ly pregnant (confirmed with positive pregnancy test), breast 
feeding, or pl anned pregnancy  during the study  or wom en of childbearing potential not 
using acceptable contraception measures.
18Study  investigators, sub -invest igators, coordinators, and their emplo yees or immediate 
family members.
5.3 Lifestyle Considerations
5.3.1 Caffeine, Alcohol, and Tobacco
During each dosing session, participants will abstain fro m ingesting caffeine -or 
xanthine -containing products (eg, coffee, tea, cola drinks, and chocolate) for 6 hours 
before and for the duration of each in -clinic study  visit.
Use of tobacco products or vaping will not be allo wed fro m 6 months pri or to Visit 1 until 
after the final fo llow-up visi t.
Clinical Study Protocol - 1.0 AstraZeneca
Breztri PT010 - D5985C00007
CONFIDENTIAL AND PROPRIETARY 30 of 78 Doc ID: TMP-0010225
Template Version Number 7.0!Participants will abstain from consuming any intoxicants (eg, alcohol) within 24 hours 
before spirometry testing.
5.3.2 Activity
Participants will abstain from strenuous exercise for 24 hours before each spirometry testing and each blood collection for clinical laboratory tests. Participants may participate in light recreational activities duri ng studies (eg, watching television, reading).
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but 
are not subsequently randomly assigned to study  intervention. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participants to meet the Consolidated Standards of Reporting Trials publishing requirements and to respond to 
queries from regulatory authorities. Minimal i nformation includes demography, screen failure 
details, eligibility criteria, and any serious AE (SAE).
Rescreening is allowed for screen failure reason(s) that are transient (including, but not 
limited to, pre-defined time period requirements,  respiratory tract infection not treated with 
systemic corticosteroids, equipment/procedure  failure, required study documentation, or 
unforeseen personal reasons).
Participants may not be rescreened due to failure to meet the study requirements of 
pre-bronchodilator FEV
1(including stability) during the screening period.
Participants on SABA alone therapy who have failed screening due to an ACQ-5 score >1.5 
could be rescreened if they have subsequently received treatment with low-dose ICS for a 
period of 4 weeks as prescribed by their treating physician (i.e. healthcare provider). If they failed screening for a second time, they must be considered screen-failures. 
Albuterol/salbutamol must be withheld for at least 8 hours prior to FEV
1measurements. If 
repeat spirometry failed, then participant must be screen-failed.
Only one rescreening is allowed in the study. Rescreened participants should be assigned the 
same participant number as for the init ial screening. Rescreened par ticipants will sign a new 
ICF. All procedures required for the screening periods, starting  should be repeated. 
Rescreening should be documented so that its effect on the study results, if any, can be 
assessed.
For all participants who are screen failures, an AE assessment and highly sensitive urine 
pregnancy test (for women of childbearing potential ) must be performed within 7 days of the 
screen failure date.CCI
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 31of 78 Doc ID: TMP -0010225
Template Version Number 7.05.5 Criteria for Temporarily Delaying 
Enrolment/Randomisation/Administration of Study Intervention
Shoul d there be an emergency situat ion (eg, COVID -19 pandemic), a risk assessment will be 
perform ed to determine if temporary  delaying of enro lment/randomisation/administration of 
study  interventi on is all owed. 
6 STUDY INTERVENTIONS AND CONCOMITANT THER APY
Study  intervent ions are all pre -specified investigational medicinal products (IMPs) and non-
investigat ional medicinal products (NIMPs), medical devices, and other intervent ions (eg, 
surgical and behavioral) intended to be administered to the study participants during the study 
conduct.
6.1 Study Intervention(s) Administered
Arm  name Treatment A HFO MDI Treatment B HFA MDI
Intervention name Pressurized inhalation 
propellant, HFOPressurized inhalation 
propellant, HFA
Type Combination product Combination product
Dose formulation MDI MDI
Unit dose strength(s) Experimental (propellant only) Refer ence (propellant only)
Dosage level(s) 4 inhalations, single dose 4 inhalations, single dose
Route of administration Oral inhalation Oral inhalation
Use Experimental Comparator
IMP and NIMP IMP   IMP
Sourcing Provided centrally by the 
sponsor Provided centrally by the 
sponsor 
Packaging and labelling Study intervention will be 
provided in an MDI. Each MDI 
will be labelled as required per 
US requirement.Study intervention will be 
provided in an MDI. Each MDI 
will be labelled as required per 
USrequirement.
Abbreviations: HFA = hydrofluoroalkane; HFO = hydrofluoroolefin; IMP = investigational medicinal product; 
MDI =metered dose inhaler ; NIMP = non -investigational medicinal product . 
Dosing instructions and dispensing details will be provided by AstraZeneca.
The HFO MDI and HFA MDI are com binat ion products (propellant + device).
Details o f the batch numbers will be included in the Trial Master File and the final clinical 
study  report ( CSR).
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C000 07
CONFIDENTIAL AND PROPRIETARY 32of 78 Doc ID: TMP -0010225
Template Version Number 7.0Study  parti cipants will be trained on the correct inhalat ion technique of the MDI (supplied by 
AstraZeneca) and other inhalers under study . Per inclusi on cri teria, parti cipants m ust 
demonstrate the proper inhalat ion technique and have the abilit y to properly  use an MDI 
device after training.
6.1.1 Medical Devices Including Combination Products with a Device 
Constituent
The AstraZeneca manufactured combinat ion products with a device constituent provided for 
use in this study  are:
HFO MDI
HFA MDI
Instructi ons for MDIs use are provided in instructions for use.
All medical device deficiencies and device constituent deficiencies (including malfunction, 
use error and inadequate labelling), hereafter referred to as medical device deficiencies, shall 
be docum ented and reported by  the invest igator throughout the clinical invest igation (see 
Secti on 7.4.1 1) and appropriately managed by the sponsor .
6.2 Preparation, Handling, Storage, and Accountability
The HFO MDIs and HF A MDIs will  be supplied by AstraZeneca as individual part icipant kits. 
A technical agreement or Item Requirement Schedule between the investigator and 
AstraZeneca will be in place to cover all pharmacy
-related activit ies, detailing roles, and 
responsibilit ies pri or to recei pt of  the study  intervent ions at the clinical unit.
A release docum ent si gned by  a pharmacist at the clinical unit will be placed in the 
appropriate section of the Trial Master File to document labelling and dispensing o f thestudy  
intervent ions to the participant.
The invest igator or designee (eg, unblinded pharmacist) must confirm appropriate 
condi tions (eg, tem perature) have been maintained during transit for all study  
intervent ion received at the site and throughout the en tire study  until authorisat ion is 
provi ded for on -site destructi on or rem oval of the study  intervent ions, reflect ing 
completion of the study . In the event of a tem perature excursio n detected at any  time 
during the study , sites will follow the reporting pro cedures for notifying AstraZeneca 
(or designated party ); release of study  intervent ions for clinical use can only occur 
once the event has been reviewed and approval is provided by AstraZeneca (or 
designated party ).
Only participants enro lled in the study  may receive study  intervent ion and only 
authori sed site staff may supply  or administer study  intervent ion. All study  
intervent ion must be stored in a secure, environmentally controlled, and mo nitored 
Clinical Study Protocol - 1.0 AstraZeneca
Breztri PT010 - D5985C00007
CONFIDENTIAL AND PROPRIETARY 33 of 78 Doc ID: TMP-0010225
Template Version Number 7.0(manual or automated) area in accordance with the labelled storage conditions with 
access limited to the investigator and authorised site staff.
∀The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for study intervention accountability, reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records).
∀Further guidance and information for the final disposition of unused study 
interventions are provided in the Pharmacy Manual.
6.3 Assignment to Study Intervention
 participants meeting all inclusion criteria and none of the exclusion criteria will be 
randomized before study intervention administration. 
Single dose study treatment will be administered via MDI device as 4 inhalations:
!Treatment A: HFO propellant only MDI; 4 inhalations per dose – test formulation
!Treatment B: HFA propellant only MDI; 4 inhalations per dose – reference 
formulation
Participants will be randomized in a ratio of 1:1 to receive treatments in one of two possible 
treatment sequences: A followed by B, or B followed by A. The single-dose treatment periods will be separated by a 3 to 12-day washout period.
All participants w ill be centr ally assigned to one of two randomized study interventions using 
an Interactive Response Technology (IRT) system. Before the study is initiated, the log-in 
information and directions for the IRT system will be provided to each site.
The IRT will provide to the investigator(s) or pharmacists the kit identif ication number to be 
allocated to the participant at the dispensing visit (as summarized in the SoA,  Table 1 ).
Routines for this will be described in the IRT user manual that will be provided to each centre.
6.4 Blinding
This study is double blinded with regard to treatment (MDI administered with 2 different 
propellants [Treatment A or B]), ie, the sponsor, the i nvestigator, all clinical staff involved in 
the clinical study, the participants, and the study monitor will remain blinded, unless safety concerns or a regulatory requirement necessitate unblinding.
The following personnel will have access to the rando mization lists from study start:
!The AstraZeneca staff carrying out the labelling and packaging of participant specific 
treatments
The randomisation code should not be broken except in medical emergencies when the CCI
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 34of 78 Doc ID: TMP -0010225
Template Version Number 7.0appropriate management of the participant requires knowledge of the treatment randomisation.
AstraZeneca retains the right to break the code for SAEs that are unexpected and are 
suspected to be causally  related to an invest igational product and that potentially  require 
expedited report ing to regulatory authorit ies. A copy o f the report, i dentifying the participant ’s 
intervent ion assignment, may be sent to invest igators in accordance with local regulat ions 
and/or sponsor policy . Rando misat ion codes will not be broken for the planned anal yses of 
data until all decisio ns on the evaluabilit y of the data from  each individual participant have 
been made and documented.
The IR T will be programmed with blind -breaking instructions. In case of an emergency , in 
which the knowledge of the specific bl inded study  intervent ion will affect the immediate 
management of the participant ’s condi tion (eg, antidote available), the invest igator has the 
sole responsibilit y for determining if unblinding of a participants ’ interventi on assignment is 
warranted. Parti cipant safet y must al ways be the first considerat ion in making such a 
determinat ion. If a participant ’s intervent ion assignment is unblinded, the sponsor must be 
notified wit hin 24 hours after breaking the blind. The investigator documents and reports the 
action to AstraZeneca, without revealing the treatment given to participant to the AstraZeneca 
staff.
6.5 Study Intervention Compliance
When participants are dosed at the site, they  will self -administer study  interventi on di rectly 
under medical supervisio n by the investigator or designee. The date, and time if applicable, of 
dose administered in the clinic will be recorded in the source documents and recorded in the 
electroni c case report form (eCRF). The dose of study  intervent ion and study  parti cipant 
ident ification will be confirmed at the time of dosing by a member of the study  site staf f other 
than the person preparing the study  intervent ion for administration.
A record of the number of actuations from HFO/HF A MDIs taken by  each parti cipant m ust be 
maintain ed and reconciled wit h study  intervent ion and co mpliance records. Intervent ion start 
and stop dates, including dates for intervent ion delays and/or dose reductions will also be 
recorded in the eCRF .
6.6 Dose Modification
Not applicable.
6.6.1 Retreatment Criteria 
Not applicable.
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 35of 78 Doc ID: TMP -0010225
Template Version Number 7.06.7 Continued Access to Study Intervention After the End of the 
Study
Not applicable.
6.8 Treatment of Overdose
For thi s study , any  dose of HFO MDI or HF AMDI greater than 4 inhalat ions once daily , is
considered an overdose.
Sponsor does not have treatm ent for an overdose. Single dosing of HFO or HFA propellant at 
Treatment Period 1 and Treatment Period 2 will be closely monitored at clinic to avoid any 
overdose.  In the event of an overdose, the invest igator/treating physician shoul d:
Evaluate th e parti cipant to determine, in consultat ion with the Study Clinical Lead, if 
possible, whether study  intervent ion shoul d be interrupted. 
Closely  monitor the parti cipant for any  AE/SAE and laboratory  abnorm alities as 
medically appropriate and at least unti l the next scheduled fo llow-up. Ref er to 
Secti on7.4.10 for details of AE/SAE reporting related to overdose.
Docum ent the quanti ty of the excess dose as well as the duration of the overdose.
6.9 Prior and Concomitant Therapy
Any medicat ion or vaccine (including over -the
-counter or prescript ion medicines, vitamins, 
and/or herbal supplements) or other specific categories of interest that the participant is 
receiving at the time o f enrolment or receives during the study must be recorded along with:
Reason for use
Dates of administration including start and end dates
Dosage information including dose, frequency, and route
The Study  Clinical  Lead shoul d be conta cted if there are any  quest ions regarding conco mitant 
or pri or therapy .
6.9.1 Prior Medications
Parti cipants eligible for this study  are requi red to be on low-dose ICS daily or low-dose
ICS/form oterol  as needed (not approved in the US), or SABA  as needed, or low-dose ICS 
whenever SABA  as needed is used (low-dose ICS as defined by  GINA  2022 in below Table4) 
for 4 weeks prior to V is
it 1.
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 36of 78 Doc ID: TMP -0010225
Template Version Number 7.0Table4 Low Daily Meter ed Dose of ICS (Monotherapy or  in Combination with 
LABA)
ICS Total Daily Dose (µg/day)
Beclomethasone dipropionate (pMDI, DPI, standard particle HFA) 200-500
Beclomethasone dipropionate (pMDI, extrafine particle HFA) 100-200
Budesonide (DPI or pMDI, standard particle HFA) 200-400
Ciclesonide (pMDI, extrafine particle HFA) 80-160
Fluticasone furoate (DPI) 100
Fluticasone propionate (DPI or pMDI, standard particle HFA) 100-250
Mometasone furoate (DPI)a200
Mometasone furoate (pMDI, standard particle HFA) 200-400
Abbreviations: DPI = dry powder inhaler; HFA = hydrofluoroalkane; ICS = inhaled corticosteroid; LABA = long -acting 
beta 2-agonist; pMDI = pressurized metered dose inhaler.
aDose depends on DPI device –see product information for more detail. Mometasone furoate 80 µg 
delivered via the Breezhaler®has been shown to be non -inferior to mometasone furoate Twisthaler®200µg 
[Buhl 2020] and can therefore be used as a permitted low- dose of ICS in this study.
6.9.2 Concomitant Medications
Any current ongoing medicat ions, including over -the-counter m edicati ons, herbal  
supplements, a nd vaccinat ions, will be allowed provided they  are not explicit ly prohibi ted by 
the protocol. Participants should also be instructed to con tact the invest igator if they develop 
any illnesses, especially those requiring medicinal intervent ions.
Medicat ions meet ing the stable dosing period prior to V isit 1 are all owed during the study  and 
listed in Table5.
Table5 Allowed Medicatio ns with Defined Stable Dosing Period Prior  to Visit 1
Medication Minimum Stable Dosing Period 
Selective serotonin reuptake inhibitors/serotonin and 
norepinephrine reuptake inhibitors a4 weeks
Tricyclic antidepressants 2 weeks
Antipsychotics 4 weeks
Anticonvulsants 52 weeks for seizure disorders b
12 weeks for other conditions
Intranasal corticosteroids 4 weeks
Intranasal antihistamines or combination products of 
intranasal antihistamines/corticosteroids4 weeks
Intranasal ipratropium bromide c4 weeks
aMust be on a stable dose for at least 4 weeks prior to Visit 1 and not altered during the screening period.
Clinical Study Protocol - 1.0 AstraZeneca
Breztri PT010 - D5985C00007
CONFIDENTIAL AND PROPRIETARY 37 of 78 Doc ID: TMP-0010225
Template Version Number 7.0bMust be free of seizures for 1 year prior to Visit 1.
cIntranasal ipratropium bromide should be withheld for at least 6 hours prior to each visit.
6.9.2.1 Vaccinations
All participants are recommended to be vaccinated with annual influenza vaccine [GINA 
2022 ] or any  other inactive/killed vaccines per local policies, availability, and affordability. If 
a participant has egg intolerance or refuses to be vaccinated, the vaccination may be omitted. 
The annual influenza vaccine can be given at  or at any other visit throughout the study 
at the discretion of the investigator; however, administration should occur after obtaining all requisite spirometry assessments for that specific test day. There should be at least 7 days between vaccination and subsequent spirometry assessments.
If a participant is being considered for enrolment into the study and also being considered for 
COVID-19 vaccination, the participant must not be randomised until at least 7 days after the last dose of vaccine or booster. If COVID-19 vaccination is in the best interest of the participant and the participant is vaccinated during the study, there should be at least 7 days between vaccination and subsequent spirometry assessments.
Live attenuated vaccines are not allowed within 30 days prior to Visit 1 or during the study.
6.9.3 Prohibited Medications
Participants requiring medications presented in  Table 6 are prohibited fro m participating in 
this study. Participants who recently discontinued use of these medications may be considered for study enrolment provided they have met the minimum cessation period prior to Visit 2. These medications are prohibited throughout the course of the study. If participants require any of the prohibited medications listed in  Table 6 , the investigator should discuss with the
medical monitor the suitability of the participant continuing study intervention.
Table 6 Prohibited Medications Throughout the Study and Prior to Visit 1
Medication Minimum Cessation Period Prior to Visit 1
LABA including formoterola48 hours
LAMA 4 weeks
Leukotriene antagonists/modifiers (eg, Zileuton®) 2 weeks (ie, 14 days)
Oral beta 2-agonist 3 months
Theophylline 3 months
Oral and intravenous corticosteroids b12 months
Injectable systemic corticosteroids (e.g., depot 
formulation, intra-articular, intraocular, intradermal, intramuscular)12 monthsCCI
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 38of 78 Doc ID: TMP -0010225
Template Version Number 7.0Table6 Prohibited Medications Thr oughout the Study and Prior  to Visit 1
Medication Minimum Cessation Period Prior to Visit 1
Any marketed (e.g., omalizumab, mepolizumab, 
benralizumab, reslizumab, tezepelumab) or investigational 
biological therapy for asthma or any other condition12 months
Any immunomodulators or immunosuppressants c3 mo nths or 5 half -lives, whichever is longer
Medications not currently licensed for use in the treatment 
of asthma and not part of current standard of care30 days
Any drug with potential to significantly pr olong the QT 
interval d14 days or 5 half -lives, whichever is longer
Other investigational drugs 30 days or 5 half -lives, whichever is longer
Live attenuated vaccines 30 days
Non-selective non -ocular β -blocking agents (except 
carvedilol)7 day s
Monoamine oxidase inhibitors 14 days
Systemic treatment with strong CYP3A4 -inhibitors (e.g., 
ketoconazole, itraconazole, and ritonavir)30 days
Systemic anticholinergics e7 day s
Herbal remedies for the treatment of allergic, 
inflammatory, or respirato ry diseases (e.g., Chinese 
complementary and alternative bronchodilatory medicines)10 days
Abbreviations: ICS = inhaled corticosteroid; LABA = long-acting beta 2-agonist;LAMA = long-acting 
muscarinic antagonist.
aParticipants using ICS/LABA as needed (not approved in the US) must withhold it for 48 hours prior to 
each study visit for spirometry purposes .
bUse of systemic corticosteroids for any other reason except for the acute treatment of a severe asthma 
exacerbation is prohibited for the dura tion of the study.
cTopical administration of immunosuppressive medication may be allowed at the discretion of the 
investigator after discussion with the study physician.
dParticipants who are on medications that have the potential to prolong the QTc interva l may  be enrolled 
provided the dose has remained stable for at least 3 months prior to Visit 1, the participant meets all of the 
electrocardiogram inclusion criteria and none of the electrocardiogram exclusion criteria, and if, in the 
opinio n of the invest igator, there are not safety concerns for the participant to participate in the study.
eIf systemic anticholinergics are used for the treatment of irritable bowel syndrome or overactive bladder and 
the treatment has been constant for at least 1 month, the y are allowed.
Specific prohibited asthma and allergy medicat ions and their required washout periods prior to 
Visit 2 are di splayed in Table7.
Table7 Prohibited Asthma and Allergy Medications During the Study Conduct 
and Requir ed W ashout Period Prior  to V isit 2
Medication Minimum Washout Period Prior to Visit 2
SABAa8 hours
Clinical Study Protocol - 1.0 AstraZeneca
Breztri PT010 - D5985C00007
CONFIDENTIAL AND PROPRIETARY 39 of 78 Doc ID: TMP-0010225
Template Version Number 7.0Table 7 Prohibited Asthma and Allergy Medications During the Study Conduct 
and Required Washout Period Prior to Visit 2
Medication Minimum Washout Period Prior to Visit 2
LABA and LABA containing medications, including 
formoterolb 48 hours
Non-sedating long- and short-acting antihistamines for systemic administration, i.e., pills (topical use of eye drops or nasal spray is allowed).7 days
Cromoglycate c7 days
Nedocromil c7 days
Ketotifen c7 days
SAMA and SABA fixed combination 7 days
Abbreviations: ICS = inhaled corticosteroid; LABA = long-acting beta 2-agonist; SABA = short-acting beta 2-
agonists; SAMA = short-acting muscarinic antagonists.
aSABA (eg, albuterol/salbutamol) must be withheld for 8 hours before spirometry  and unscheduled visits (if applicable).  
bParticipants using ICS/LABA as needed (not approved in the US) must withhold it for 48 hours prior to 
each study visit for spirometry purposes. 
cCromoglycate, nedocromil, and ketotifen eye drops are allowed for allergic conjunctivitis; no washout 
period.
6.10 Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
Discontinuation of specific sites or of the study as a whole are handled as part of  Appendix A .
6.11 Discontinuation of Study Intervention
Note that discontinuation from study intervention is notthe same thing as a discontinuation or 
withdrawal from the study (see Section  6.12 ).
If study intervention is permanently discontinued, the participant should, if at all possible, 
remain in the study. See the SoA (Table 1 ) for data to be collected at the time of 
discontinuation of study intervention and follow-up and for any further evaluations that need to be completed.
If a participant experiences any of the changes listed below, the study intervention must be 
discontinued:
!Development of exclusion criteria or other safety reasons as judged by the investigator
during the treatment periods
!Pregnancy (Section  7.4.8 )
6.12 Participant Discontinuation/Withdrawal from the Study
Discontinuation of the participant from the study by the investigator:CCI
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 40of 78 Doc ID: TMP -0010225
Template Version Number 7.0A participant may be discontinued from the study  at any  time at the di scret ion of the 
investigator for safet y, behavioural, co mpliance, or admi nistrative reasons.
At the time of discont inuing from the study , if the parti cipant has not been discont inued 
from the study  intervent ion, see Section 6.11. 
Voluntary  withdrawal from  the study  by the participant:
A participant may withdraw fro m the study  at any  time at the participant’s own request 
for any  reason (or wi thout provi ding any  reason).
A participant who wishes to withdraw fro m the study  must be inform ed by  the 
investigator about modified fo llow-up opti ons. A parti cipant shoul d be advised to fo llow 
his/her usual maintenance therapy  prescribed by  his/her physician and a withdrawal visit 
or a follow -up call  should be scheduled. 
If the partici pant wi thdraws consent for disclosure of future informat ion, AstraZeneca 
may retain and cont inue to use any data collected before such a withdrawal o f consent.
If the participant withdraws fro m the study , AstraZeneca m ay retain and cont inue to use 
any samp les collected before such a withdrawal of consent for the purposes the 
participant ori ginally  consented unless the participant withdraws consent for use of 
samples already  collected. If the parti cipant specifically wit hdraws consent for any use of 
samples, it must be docum ented in the site study  records by  the invest igator and the 
investigator must inform the local and glo bal study teams. Destruction of any samples 
taken and not y et tested shoul d be carri ed out in line wi th docum ented sam ple wi thdrawal  
wishes in conjunct ion with what was stated in the informed consent and local regulat ion.
6.13 Lost to Follow -up
A participant will be considered lost to fo llow-up if the partici pant repeatedly failsto return 
for scheduled visit s and isunable to be contacted by  the study  site.
The fo llowing acti ons m ust be taken if a participant fails to return to the study  site for a 
requi red study  visit:
The site must attempt to contact the participant and reschedule the missed visit as soon as 
possible. The participant should be counseled on the importance of maintaining the 
assigned visit schedule. At this time ascertain whether the participant should or wishes to 
or continue in the study .
Before a participant is deemed lost to fo llow-up, the invest igator or designee must make 
every effort to regain contact with the participant (where possible, telephone calls, texts, 
emails, and if necessary , a certified l etter to the parti cipant’s last known mailing address 
or local equivalent methods). These contact attempts should be document ed in the 
participant’s m edical  record.
Clinical Study Protocol - 1.0 AstraZeneca
Breztri PT010 - D5985C00007
CONFIDENTIAL AND PROPRIETARY 41 of 78 Doc ID: TMP-0010225
Template Version Number 7.0!Should the participant continue to  be unreachable, the participant w ill be considered to 
have withdrawn from the study. 
7 STUDY ASSESSMENTS AND PROCEDURES
!Study procedures and their timing are summarised in Section  1.3, SoA ( Table 1 ). Protocol
waivers or exemptions are not allowed.
!Spirometry SHOULD be performed in accordance with the specified timing as 
indicated in the SoA (Table 1 ).
!Urgent safety concerns should be discussed with AstraZeneca immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
study intervention.
!Adherence to the study design requirements, including those specified in the SoA 
(Table 1 ), is essential and required for study  conduct.
!All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The i nvestigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.
!Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of the ICF may be utilised for screening or baseline purposes provided the procedures met the protocol-specified criteria and were performed within the time fr ame defined in the SoA (Table 1 ).
!Instructions for the collection and handling of human biological samples (HBS) will be 
provided in the study-specific laboratory manual. Samples should be stored in a secure 
storage space with adequate measures to protect confidentiality. For further details on handling of HBS, see  Appendix C .
!In the event of a significant study continuity issue (eg, caused by a pandemic), alternate 
strategies for participant visits, assessmen ts, medication distribution and monitoring may 
be implemented by AstraZeneca or the investigator, as per local health authority/ethics requirements.  
!The maximum amount of blood collected from each participant over the duration of the 
study, including any extra assessments that may be required, will not exceed 50 mL or 
will be in adherence to local laboratory standards. Repeat or unscheduled samples may be 
taken for safety reasons or for technical issues with the samples.
7.1 Administrative and General/Baseline Procedures
7.1.1 Demographics and Medical/Surgical History
Demographics and medical/surgical history will be collected  and updated during the 
screening period, if necessary. CCI
Clinical Study Protocol - 1.0 AstraZeneca
Breztri PT010 - D5985C00007
CONFIDENTIAL AND PROPRIETARY 42 of 78 Doc ID: TMP-0010225
Template Version Number 7.07.1.2 Height and Weight
Height and weight will be measured as specified in the SoA (Table 1 ). Body  mass index will 
be automatically calculated in the eCRF.
7.1.3 Physical Examinations
A complete physical examination will be performed on all participants at screening and withdrawal (if applicable). A brief physical examination will be performed on all participants 
 prior to dose (Section  1.3, SoA).
!A complete physical examination will be performed and include assessments of the 
following; general appearance, respiratory, cardiovascular, abdomen, skin, head and neck (including ears, eyes, nose, and throat), ly mph nodes, thyroid, musc uloskeletal (including 
spine and extremities), and neurological systems. 
!A brief physical examination will include, at a minimum, assessments of the skin, lungs, 
cardiovascular system, and abdomen (liver and spleen).
7.1.4 Vital Signs
Vital signs will be performed at timelines as specified in Section  1.3, SoA .
The following variables will be collected after the participant has rested in the supine position 
for at least 5 minutes:
!Systolic blood pressure (mmHg)
!Diastolic blood pressure (mmHg)
!Pulse rate (beats per minute)
!Body temperature (°C)
!Respiratory rate (breaths per minute)
The measurement of vital signs will be carried out according to the relevant site standard 
operating procedures.
7.1.5 Electrocardiograms
12-lead ECG will be performed at timepoints as specified in Section  1.3, SoA.
The 12-lead ECG will be taken in supine position after 10 minutes of rest. The investigator or 
authorized delegate will be responsible for the overall interpretation and determination of clinical significance of any potential ECG findings. In case of discrepancy between the investigator’s interpretation and that provided by the ECG machine (if applicable), the investigator’s interpretation will take precedence and should be noted on the printout and recorded in the eCRF. A copy of the ECG will be produced and quality checked and kept in CCI
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 43of 78 Doc ID: TMP -0010225
Template Version Number 7.0case of further need for re -evaluat ion.
7.1.6 Clinical Laboratory Tests
Blood and urine samples for determinat ion of clinical chemistry , haematol ogy, and urinal ysis 
will be taken at the visits indicated in the SoA.
Addit ional samples may  be collected if clinically indicated at the discretion of the invest igator . 
The clinical chemistry , haematol ogy, and urinalysis will be performed at local laboratory . 
The fo llowing laboratory  variables will be measured (see Table8). 
Table8 Laboratory V ariables
Haematology/Haemostasis (whole blood) Clinical Chemistry (serum or plasma)
B-Haemoglobin (Hb) S/P-Creatinine
B-Leukocy te count S/P-Bilirubin, total
B-Leukocy te differential count (absolute count) S/P-Alkaline phosphatase (ALP)
B-Platelet count S/P-Aspartate transaminase (AST)
S/P-Alanine transaminase (ALT)
Urinalysis (dipstick) S/P-Albumin
U-Hb/Ery throcy tes/Blood S/P-Potassium
U-Protein/Albumin S/P-Calcium, total
U-Glucose S/P-Sodium
S/P-Creatine kinase (CK)
7.2 Efficacy Assessments
Not applicable.
7.3 Safety Assessments
Planned time po ints for all safet y assessments are provided in Section 1.3, SoA .
7.3.1 Asthma Control Questionnaire 5
Asthma Control Quest ionnaire 5 will only be assessed during screening (V isit 1) for 
participants ’ eligibilit y.
Clinical Study Protocol - 1.0 AstraZeneca
Breztri PT010 - D5985C00007
CONFIDENTIAL AND PROPRIETARY 44 of 78 Doc ID: TMP-0010225
Template Version Number 7.0The ACQ [Juniper 1999a ] was developed to measure asthma control and has been fully 
validated for use in adults (18 years and older) and children 6 to 17 years of age. International 
guidelines for the treatment of asthma have identified that the primary clinical goal of asthma management is to optimize asthma control ( minimization of symptoms, activity limitation, 
bronchoconstriction, and rescue bronchodilator use) and thus reduce the risk of life-
threatening exacerbations and long-term m orbidity. The ACQ was developed to meet these 
criteria by measuring both the adequacy of asthma control and change in asthma control, which occurs either spontaneously or as a result of treatment.
The ACQ-5 scores are supported en tirely by patien t-reported symptoms. Participants are asked 
5 symptom questions. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ-5 score is the mean of the responses to items 1 to 5. 
A mean score of ≤0.75 indicates well-controlled asthma, scores between 0.75 and < 1.5 
indicate partly controlled asthma, and a score ≥1.5 indicates not well-controlled asthma 
[Juniper 2006 ]. Individual changes of at least 0.5 are considered clinically meaningful. 
7.3.2 Spirometry
Spirometry will be performed at the following timepoints (see SoA  Table 1 ):
!  
 
 
Spirometry will be performed by a technologist or a qualified designee to ensure participants 
achieve optimal lung function and using standardized equipment that meets or exceeds the 
American Thoracic Society/European Respiratory Society joint recommendations [Miller 2005 ].
If FEV
1 drops > 15% from baseline, measurements should be repeated at Investigator’s 
discretion until FEV 1values are within 10% of baseline performed that day.
The participant will be in a seated position dur ing spirometry. The following variables will be 
recorded:
!FEV 1
!FEV 1percentage of predicted value
Spirometry must meet both acceptability and repeatability criteria according to American 
Thoracic Society/European Respiratory Society 2019 recommendations [Graham 2019 ]. CCI
Clinical Study Protocol - 1.0 AstraZeneca
Breztri PT010 - D5985C00007
CONFIDENTIAL AND PROPRIETARY 45 of 78 Doc ID: TMP-0010225
Template Version Number 7.0Calculated predicted spirometry results will be obtained using the Global Lung Initiative 
equations [Quanjer 2012 ].
7.3.2.1 Monitoring for Bronchospasm
 
  
 
 
Note: FEV 1 measurement at post-dose 30 minutes is for exploratory safety assessment, but not 
as part of the bronchospasm definition.
7.3.3 Other Safety Assessments
7.3.3.1 Pregnancy testing
A serum pregnancy test ( β-human chorionic gonadotropin) will be conducted at  and 
urine β-human chorionic gonadotropin tests at the following visits for women of childbearing 
potential, as specified in the SoA (Table 1 ).
A serum follicle-stimulating hormone test w ill be conducted at  only, for women who 
have been amenorrhoeic for 12 months without an alternative medical cause, to confirm postmenopausal status.
For all participants who are screen failures, a highly sensitive urine pregnancy test (for women 
of childbearing potential) must be performed within 7 days of the screen failure date.
7.4 AEs, SAEs, and Other Safety Reporting
The Investigator is responsible for ensuring that all staff involved in the study are familiar 
with the content of this section.
The definitions of an AE or SAE can be found in  Appendix B .
The definit ions of medical device-related safety events (medical device AEs and adverse 
device effects [ADEs], medical device SAEs, serious adverse device effects [SADEs], unanticipated serious adverse device effects [USADEs], and medical device deficiencies), can be found in  Appendix D . Medical  device deficiencies are covered in Section  7.4.11 .
Parti cipants (or, when appropriate, a caregiver, surrogate, or the participant’s legally 
authorised representative) will notify the investigator or designees of symptoms. These must CCI
CCI
CCI
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 46of 78 Doc ID: TMP -0010225
Template Version Number 7.0then be assessed by the investigator and if considered an AE it will be reported by  the 
investigator.
The invest igator and any designees are responsible for detecting, document ing, and recording 
events that meet the definit ion of an AE.
AE variables
The fo llowing variables will be collected for each AE:
AE (verbat im)
The date and time when the AE started and stopped
Maximum intensit y
Whether the AE is serious or not
Invest igator causalit y rating a gainst the study  intervent ions (yes or no)
Action taken with regard to study  intervent ions
AE caused participant’s withdrawal fro m the study (y es or no)
Outcom e
In addit ion, the fo llowing vari ables will be collected for SAEs:
Date AE m et cri teria for SAE
Date invest igator became aware of SAE
AE description
AE is seri ous due to
Date of hospitalisat ion
Date of discharge
Probable cause of death
Date of death
Autopsy  performed
Causalit y assessment in relat ion to study  procedure(s)
Causalit y assessment to other medicat ion
7.4.1 Time Period and Frequency for Collecting AE and SAE Information
Adverse events will be collected from time of signature of the ICF throughout the treatment 
period and including the fo llow-up peri od.
If the invest igator becomes aware of an SAE with a suspected causal relat ionship to the IMP 
that occurs after the end of the clinical study  in a treated parti cipant, the invest igator shall, 
Clinic al Study  Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 47of 78 Doc ID: TMP -0010225
Template Version Number 7.0without undue del ay, report the SAE to AstraZeneca.
7.4.2 Follow- up of AEs and SAEs
Any AEs that are unreso lved at the participant ’s last AE assessment in the study are fo llowed 
up by  the invest igator for as long as medically indicated, but without further recording in the 
eCRF . AstraZeneca retains the right to request additional information for any  parti cipant wi th 
ongoing AE(s)/SAE(s) at the end of the study , if judged necessary .
7.4.3 Causality Collection
The invest igator should assess causal relationship between study intervention and/or 
investigat ional medical devices and each AE, and answer ‘yes’ or ‘no’ to the question ‘Do y ou 
consider that there is a reasonable possibilit y that the event may  have been caused by the 
IMP? ’
For SAEs ,causal relat ionship should also be assessed for other medicat ion and study  
procedures and/or medical devices. Note that for SAEs that could be associated with any study  
procedure the causal relat ionship is implied as ‘yes’.
A guide to the interpretation of the causalit y question is found in Appendix B. For m edical 
devices, a guide to the interpretation of the causalit y quest ion can be found in Appendix D.
7.4.4 AEs Based on Examinations and Tests
Deteri oration as com pared to baseline in protocol -mandated l aboratory  values, vital 
signsshoul d only  be reported as AEs if they meet any of the fo llowing:
fulfil any  of the SAE cri teria
are the reason for discont inuat ion of the study  intervent ions
are clinically  relevant as j udged by the invest igator (which may include but is not limited 
to consi derat ion as to whether intervent ion or non -planned visits were required or other 
action was taken wit h the IMP, eg, dose adjust ment or drug interruption).
If deteri oration in a laboratory  value/vi tal sign i s associ ated wi th clinical signs and symptoms, 
the sign or symptom  will be reported as an AE and the associated laboratory  resul t/vital sign 
will be considered as addit ional informat ion. Wherever possible, the reporting invest igator 
uses the clinical, rather than the laboratory  term  (eg, anaemia vs low haemoglo bin value). In 
the absence of clinical signs or symptoms, clinically relevant deteriorations in non -mandated 
param eters shoul d be reported as AE(s).
Deteri oration of  a laboratory  value, which is unequivocally due to disease progression, should 
not be reported as an AE/SAE.
Any new or aggravated clinically relevant abnormal medical finding at a physical examinat ion 
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 48of 78 Doc ID: TMP -0010225
Template Version Number 7.0as com pared wi th the baseline assessme nt will be reported as an AE.
The results from the protocol mandated laboratory  tests and vital signs will be summarised in 
the CSR. 
7.4.5 AEs Based on Signs and Symptoms
All signs or symptoms spontaneously  reported by  the parti cipant or reported in response to the 
open question fro m the study  site staf f: “Have y ou had any  heal th probl ems since the previous 
visit/you were last asked?” , or revealed by observation will be collected and recorded in the 
eCRF . 
When co llecting AEs, the recording of diagnoses is prefe rred (when possible) to recording a 
list of signs and symptoms. However, if a diagnosis is known and there are other signs or 
symptoms that are not generally part of the diagnosis, the diagnosis and each sign or symptom 
will be recorded separately.
7.4.6 Adverse Events of Special Interest
Adverse events of special interest in this study  are respi ratory  events such as dysphonia, 
cough, dyspnoea, wheezing, bronchospasm, and asthma exacerbat ions. 
For the purpose of this study, an event of bronchospasm is defined as a reducti on in FEV 1of 
>15% from baseline (ie, the FEV 1 value obtained within 30 minutes prior to study  
intervent ion administration) at 5 or 15 minutes post -dose with associated symptoms of 
wheezing, shortness of breath, or cough.
An asthma exacerbat ion is defined as worsening of asthma that requires a medical 
intervent ion. 
A moderate asthma exacerbat ion is defined as worsening of asthma symptoms (shortness of 
breath, wheezing, chest tightness, cough) that result in addit ional ICS treatment for at least 
3days.
The worsening o f asthma includes deterioration in at least one of the fo llowing:
asthma symptoms (eg, shortness of breath, wheezing, chest tightness, cough)
night -time awakening due to asthma
physical exam finding consistent with deterioration of asthma
An asthma exacerbat ion will be considered severe if it results in at least one of the fo llowing:
A short course of systemic corticosteroids for at least 3 consecutive days to treat
symptoms of asthma worsening
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 49of 78 Doc ID: TMP -0010225
Template Version Number 7.0An emergency  room  or urgent care visit (defined as evaluat ion and treatment for 
< 24 hours in an emergency department or urgent care centre) due to asthma that 
requi red treatm ent wi th systemic corti costeroi ds
An in-patient hospi talizat ion (defined as admission to an in -patient facility and/or
evaluat ion and treatment in a healt h care facilit y for ≥ 24 hours) due to asthma
Death rel ated to asthma
7.4.7 Reporting of SAEs
All SAEs must be reported, whether or not considered causally related to the study 
intervent ions. All SAEs will be recorded in the eCR F.
If any SAE occurs during the study , investi gators or other si te personnel will inform the 
appropriate AstraZeneca representatives wit hin 1 day , ie, immediately but no later  than 
24hours of when he or she beco mes aware of it .
The designated AstraZeneca representative will work with the investigator to ensure that all 
the necessary information is provided to the AstraZeneca Pat ient Safet y data entry  site within 
1calendar  day of initial receipt for fatal and life -threatening events and within 5 calendar
days of initial receipt for all other SAEs.
For fatal  or life -threatening AEs where important or relevant informat ion is missing, active 
follow-up will be undertaken immediately . Invest igators or other site personnel will inform 
AstraZeneca representatives of any follow-up informat ion on a previously  reported SAE 
within one calendar day , ie, immediately  butno later  than 24 hours of when he or she 
beco mes aware of it .
Once the invest igators or other site personnel indicate an AE is seri ous in the electroni c data 
capture (EDC) sy stem , an autom ated em ail alert is sent to the designated AstraZeneca 
representative.
If the EDC system is not available, then the investigator or other study  site staf f reports the 
SAE via secure method to the appropriate AstraZeneca r epresentative.
When the EDC is temporarily not accessible, the AstraZeneca study  representative should 
confirm that the invest igator/site staff enters the SAE in the AstraZeneca EDC when access 
resum es.
For further guidance on the definit ion of an SAE, see Appendix B.
The reference document for definit ion of expectedness/listedness is the IB for the AstraZeneca 
study  interventi ons. For HFO MDI and HF A MDI, no serious adverse reactions (SARs) are 
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 50of 78 Doc ID: TMP -0010225
Template Version Number 7.0considered expected by  the sponsor for the purpose of expedited reporting of suspected 
unexpected serious adverse reactions (SUSARs). Any AE that is deemed to be related to the 
study  drug by  the investi gator or the company , which is also serious will be treated as a 
SUSAR and appropriately expedited.
7.4.8 Pregnancy
All pregnancies and outcomes of pregnancy should be reported to AstraZeneca except:
If the pregnancy  is discovered before the study  parti cipant has receive d any  study  
intervent ion
Pregnancies in the partner of male participants
7.4.8.1 Maternal Exposure
If a participant beco mes pregnant during the study , study  intervent ion shoul d be discont inued 
immediately .
Pregnancy itself is not regarded as an AE unless there is a suspicio n that the study  intervent ion 
may have interfered with the effect iveness of a contraceptive medicat ion. Congenital 
anomalies/bi rth defects and spontaneous miscarriages should be reported and handled as 
SAEs. Elective abortions wit hout complicat ions should not be handled as AEs. The outcome 
of all pregnancies (spontaneous miscarriage, elect ive terminat ion, ectopic pregnancy , normal  
birth, or congenital ano maly/birth defect) should be fo llowed up and docum ented even if the 
participant was discont inued from the study .
If any pregnancy  occurs during the study , then the investigator or other site personnel informs 
the appropriate AstraZeneca representatives immediately but no later than 24 hours after he or 
she becomes aware of it.
The designated AstraZeneca representative works with the invest igator to ensure that all 
relevant informat ion is provided to the AstraZeneca Pati ent Safet y data entry  site within 1 or  
5calendar  days for pregnancies associated with SAEs (see Sect ion 7.4.7 ) and within 30 days
for all other pregnancies.
The same timelines apply when outcome informat ion is available.
The PREGREP module in the eCRF is used to report the pregnancy  and the paper -based 
PREGOUT module is used to report the outcome of the pregnancy .
7.4.8.2 Paternal Exposure 
There i s no restri ction on fathering children or donating sperm during the study .
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C0 0007
CONFIDENTIAL AND PROPRIETARY 51of 78 Doc ID: TMP -0010225
Template Version Number 7.07.4.9 Medication Error, Drug Abuse, and Drug Misuse
7.4.9.1 Timelines
If an event of medication error , drug abuse, ordrug misuse occurs during the study , then the 
investigator or other site personnel informs the appropriate AstraZeneca representatives within 
1 calendar  day, ie, immediately  but no later  than 24 hour sof when they  become aware of i t. 
The designated AstraZeneca representative works with the invest igator to ensure that all 
relevant informat ion is completed wi thin 1(initial fatal/life-threatening or fo llow-up 
fatal/life-threatening) or 5(other serious initial and fo llow-up) calendar  days if there is an 
SAE associated with the event of m edicat ion error, drug abuse, or misuse (see Section 7.4.7 ) 
and within 30 days for all other events .
7.4.9.2 Medication Error
For the purposes of this clinical study , a m edicat ion error is an unintended failure or mistake 
in the treatment process for an IMP or AstraZeneca NIMP that either causes harm to the 
participant or has the potential to cause harm to the participant.
The full defini tion and examples of medicat ion error can be found in Appendix B 4.
7.4.9.3 Drug Abuse
Drug abuse is the persistent or sporadic intentional , non -therapeutic excessive use of IMP or 
AstraZeneca NIMP for a perceived reward or desired non -therapeuti c effect.
The full definit ion and examples o f drug abuse can be found in Appendix B
4.
7.4.9.4 Drug Misuse
Drug misuse is the intentional and inappropriate use (by a study participant) of IMP or 
AstraZeneca NIMP for medicinal purposes outside of the authorised product informat ion, or 
for unauthorised IMPs or AstraZeneca NIMPs, outside the intended use as specified in the 
protocol  and includ es deliberate administration of the product by  the wrong route.
The full definit ion and examples o f drug misuse can be found in Appendix B
4.
7.4.10 Report ing of Overdose
Refer to Section
 6.8for definit ion and treatment of overdose.
An overdose with associated AEs is recorded as the AE diagnoses/symptoms on the 
relevant AE m odules in the eCRF and on the Overdose eCRF module.
An o verdose without associated symptoms is only reported on the Overdose eCRF 
module.
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 52of 78 Doc ID: TMP -0010225
Template Version Number 7.0If an overdose on an IMP or AstraZeneca NIMP occurs in the course of the study , the 
investigator or other site personnel inform appropriate AstraZeneca representatives 
immed iately , but no later  than 24 hours of when he or she beco mes aware of it.
The designated AstraZeneca representative works with the invest igator to ensure that all 
relevant informat ion is provided to the AstraZeneca Pati ent Safet y data entry  site within 1 o r 
5calendar  days for overdoses associated with an SAE (see Section 7.4.7 ) and within 30 days
for all other overdoses.
7.4.11 Medical Device Deficiencies
Combinat ion products with a device const ituent (MDIs and DPIs) are being provided for use 
in this study . In order to fulfil regulatory  reporti ng obligat ions worldwide, the investigator is 
responsible for the detection and documentation of events meet ing th e definit ion of a medical 
device deficiency that occur during the study  with thecombination products.
Medical device deficiencies fro m this study  will be collected and monitored to ensure the 
safet y of parti cipants and improve the safety  and perform ance o f the device.
Medical device deficiencies will not be presented in the CSR, but where required by  local 
regul ations, deficiencies will be summarised in the relevant periodic report.
The definit ion of a medical device deficiency  is aninadequacy of a medica l device/device 
constituent with respect to its ident ity, qualit y, durabilit y, reliabilit y, safet y, or perform ance. 
Medical device deficiencies include malfunct ions, use errors, and information supplied by the 
manufacturer .
NOTE: Deficiencies fulfilling th e definit ion of an AE/SAE will also fo llow the processes 
outlined in Appendix D.
The AstraZeneca Clinical Study  Medical Device/Device Const ituent Repo rt Form and/or 
Product Complaint Intake Form will be used to collect the deficiency .
7.4.11.1 Time Period for Detecting Medical Device Deficiencies
Medical device incidents or malfunct ions of the medical device will be detected, 
docum ented, and reported during all periods of  the study  in which the medical device is 
used.
If the invest igator learns of any medical device deficiency at any t ime after a participant 
has been discharged from the study , and such incident is considered reasonably related to 
a medical device provi ded for the study , the invest igator will pro mptly notify  
AstraZeneca.
The m ethod of docum enting medical device deficiencies is provided in Appendix D.
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 53of 78 Doc ID: TMP -0010225
Template Version Number 7.07.4.11.2 Follow -up of Medical Device Deficiencies
Follow-up applies to all participants, including those who discont inue study  intervent ion.
The invest igator is responsible for ensuring that follow -up includes any supplemental 
investigat ions as indicated to elucidate the nature and/or causalit y of the deficiency.
New or updated informat ion will be recorded on the original form used to report the 
deficiency, with all changes signed and dated by  the invest igator.
7.4.11.3 Prompt Reporting of Medical Device Deficiencies to Sponsor
Medical device deficiencies will be reported to AstraZeneca wit hin 24 hours after the 
investigator determines that the event meets the protocol definit ion of a medical device 
deficiency.
The AstraZeneca Clinical Study  Medical Device/Device Const ituent Report Form and/or 
Product Complaint Intake Form will be sent to AstraZeneca by  email. Ifemail is 
unavailable, then faxshoul d be ut ilised.
Where an SAE has occurred in addit ion to the malfunct ion, the SAE will be recorded in 
the eCRF as detailed in Sect ion 7.4.7 .
AstraZeneca will be the contact for the receipt of medical device deficiency reports.
7.4.11.4 Regulatory Reporting Requirements for Device Deficiencies
The invest igator will pro mptly report all medical device deficiencies occurring with any 
medical device provided for use in the study  inorder for AstraZeneca to fulfil the legal 
responsibilit y to notify appropriate regulatory  authori ties and other entit ies about certain 
safet y informat ion relating to medical devices being used in clinical studies.
The invest igator, or responsible person a ccording to local requirements (eg, the head o f 
the medical inst itution), will co mply with the applicable local regulatory  requi rements 
relating to the reporting o f medical device deficiencies to the institutional review board 
(IRB).
For further guidance o n the definit ion of an SAE, see Appendix D.
7.5 Pharmacokinetics
Not applicable.
7.6 Pharmacodynamics
Not applicable.
7.7 Optional Genomics Initiative
Optional Genomics Ini tiative research is not applicable in this study . 
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 56of 78 Doc ID: TMP -0010225
Template Version Number 7.0Analyses will be perfor med by the sponsor or its representatives. Demographic and baseline 
characterist ics data will be summarised by treatment sequence. Categorical variables will be 
summarised using frequency  and percentages, where the denominator for calculat ion is the 
underl ying analysis set populat ion unless otherwise specified. Continuous variables will be 
summarised with descript ive statist ics using number of available observat ions, m ean, standard 
deviat ion, median, minimum, and maximum, and quartiles where appropriate.
Specific details regarding the statistical analyses will be provided in the SAP .
8.4.1.1 Intercurrent Events
Relevant intercurrent events (ICEs) include use of any leukotriene receptor antagonists 
(LTRA’s)or any inhaled bronchodilator within the restrict edtime win dow prior to a clinic 
visit that woul d directly affect airway calibre and the primary and exploratory  endpo ints. 
8.4.1.2 Strategy for Intercurrent Events
If use o f an LTRAor any inhaled bronchod ilator occur s prior to a scheduled clinic visit , 
optimally , the FEV 1assessment should be delayed ( time permitting) or rescheduled.  
However, if a spiro metry assessment i s perform ed and it ’s later discovered and confirmed that 
a
nLTRA or any inhaled bronchodilator was used within the restricted window prior to the 
clinica l visit, the result ing data fro m that visitwill not be included in the primary  and 
exploratory  analysis ,and will be considered a n important protocol deviat ion.  
8.4.2 Safety
Safety data will be presented using descript ive statist ics unless otherwise specified .
8.4.2.1 Primary Endpoint
The primary  endpoint is defined as change from baseline in FEV 1 AUC 0-15 min post-dose. The 
analysis will be performed based on the Safet y Analysis Set using a Principal Stratum 
estimand .
Change in FEV 1AUC 0-15 min post-dose will be calc ulated fro m FEV 1change fro m baseline at 5 
and 15 minutes post -dose using the trapezoidal rule, divided by the actual observat ion time 
from the first to the l ast non -missing value, for each treatment period. Baseline is the FEV 1
value obtained within 30 mi nutes pri or to study  intervent ion administration in each treatment 
period.
A Mixed Model Repeated Measures analysis wit h treatment sequence, period, average 
baseline FEV 1, and treatm ent as fixed effects, and participant within sequence as the rando m 
effect will be used. Average baseline (period -specific baseline FEV 1averaged over the 
treatm ent peri ods) is included to account for cross -level bias. Adjusted mean change from 
baseline est imates per treatment group and corresponding 2 -sided 95% CIs al ong with an 
overall est imate of the treatment difference (HFO MDI minus HFA MDI) will be presented. If 
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 57of 78 Doc ID: TMP -0010225
Template Version Number 7.0the lower limit of the 2 -sided 95% CI for the difference in mean change from baseline of HFO 
MDI minus HFA MDI is > −200 m L, the null hypothesis of inferiori ty will be rejected and NI 
will be demo nstrated.
Descript ive summaries for FEV 1at 30 minutes pre -dose, 5 and 15 minutes post -dose, and 
change in FEV 1 AUC 0-15 min post-dose, will be reported by treatment and period.
8.4.2.2 Secondary Endpoints
8.4.2.2.1 Cumulative Incidence of Br onchospasm
An event of bronchospasm is defined as a reduction in FEV 1of >15% fro m baseline (ie, the 
FEV 1value obtained within 30 minutes prior to study  intervent ion administration) at 5 or 
15minutes post -dose with associated symptoms of wheezing, shortness of breath, or cough.
The secondary  endpoint i s defined as cumulative incidence of bronchospasm events . The 
analysis will be performed based on the Safet y Analysis Set. McNemar ’s test for the 
bronchospasm event rate analysis will be applied given the crossover design. For each 
treatm ent, the proporti on of  parti cipants who experience an event along wit h the 2- sided 95% 
CI (if applicable) will be reported. The difference in proportions alo ng with the 2- sided 95% 
CI (if applicable) will also be repor ted.  
8.4.2.2.2 Adverse Events
Adverse events will be coded using the most recent versio n of the Medical Dict ionary for 
Regulatory  Activities that will have been released for execution at AstraZeneca/designee. All 
AE summaries will be performed based on Safety  Anal ysis Set. 
Adverse events will be presented for each treatment and for each treatment period by  system  
organ class, and/or preferred term covering number and percentage of participants reporting at 
least one event and number of events where appropriate. Th e number and rate of AEs will be 
summarized for each treatment.
An overview of treatment -emergent AEs will be presented for each treatment group 
summarizing the number and percentage of participants with any  AE, AEs wit h outcome of 
death, serious AEs, and AEs leading to discont inuation of IP as well as the number of 
individual occurrences in those categories.
Separate AE tables will be provided taken into consideration relationship as assessed by the 
investigator, maximum intensit y, seriousness, death, and events l eading to di scont inuat ion of 
IP as well as other action taken related to IP .
An addit ional table will be presented summarizing the number and percentage of participants 
with most comm on AEs.
Clinical Study Protocol - 1.0 AstraZeneca
Breztri PT010 - D5985C00007
CONFIDENTIAL AND PROPRIETARY 58 of 78 Doc ID: TMP-0010225
Template Version Number 7.0Full details of AE analyses will be provided in the SAP.
 
8.4.3 Other Analyses 
8.4.3.1 Physical Examinations
Physical examination data will be presented in a data listing.
8.4.3.2 Vital Signs
Vital signs data will be presented in a data listing.
8.4.3.3 Electrocardiogram
Electrocardiogram data will be presented in a data listing.
8.5 Interim Analyses 
No interim analysis is planned.
8.6 Data Monitoring/Other Committee
Not applicable. 
9 SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONSCCI
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 59of 78 Doc ID: TMP -0010225
Template Version Number 7.0Appendix ARegulatory, Ethical, and Study Oversight Considerations
A 1 Regulatory and Ethical Cons iderations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki as amended at 64th WMA General Assembly, Fortaleza, 
Brazil, October 2013 and Council for International Organizations of Medical 
Sciences Internat ional Ethical Guidelines
Applicable Internat ional Council for Harmonisation (ICH) Good Clinical Practice 
(GCP) gui delines
Applicable laws and regulations
The protocol , revised protocol, ICF, IB, and other relevant documents (eg, 
advert isements) must be submitted to an IRB by the invest igator and reviewed and 
approved by  the IRB before the study  is initiated.
Any revised protocol will require IRB and applicable Regulato ry Authori ty approval  
before implementation of changes made to the study design, except for changes necessary 
to eliminate an immediate hazard to study  parti cipants.
AstraZeneca will be responsible for obtaining the required authorisations to conduct the 
study from the concerned Regulatory  Authori ty. This responsibilit y may be delegated to a 
CRO, but the accountabilit y remains wi th AstraZeneca.
The invest igator will be responsible for providing oversight of the conduct of the study at 
the site and adherence to requirements of 21 Code of Federal Regulat ions (CFR) 312.120, 
ICH guidelines, the IRB, European Regulation 536/2014 for clinical studies (if 
applicable), European Medical Device Regulat ion 2017/745 for clinical device research 
(if applicable), and all other applicable local regulations.
Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by the invest igator to AstraZeneca of an SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies towards the safet y of parti cipants and the safet y of 
a study  intervent ion under clinical invest igation are m et.
AstraZeneca has a legal responsibilit y to notify both the local regulatory  authori ty and 
other regulatory  agencies about the safet y of a study  intervent ion under clinical 
investigat ion. AstraZeneca will co mply with country -specific regulatory  requi rements 
relating to safet y reporting to the regulatory  authorit y, IRB, and invest igators.
For all studies except those utilising medical devices, invest igator safet y reports must be 
prepared for suspected unexpected serious adverse reactions according to local regulatory 
requi rements and sponsor policy and forwarded to investigators as necessary .
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 60of 78 Doc ID: TMP -0010225
Template Version Number 7.0Adherence to European Medical Device Regulat ion 2017/745 for clinical device research 
(if applicable), and all other applicable local regulations
An invest igator who receives an invest igator safety report describing an SAE or other 
specific safet y informat ion (eg, summary or list ing of SAEs) fro m AstraZeneca will 
review and then file it along wit h the IBand will notify the IRB, if appropriate according 
to local requi rements.
Regulatory Reporting Requir ements for  Serious Br eaches
Prom pt notificat ion by the invest igator to AstraZeneca of any (potential) serious breach of 
the protocol or regulations is essen tial so that l egal and ethi cal obligat ions are met.
A ‘serious breach’ means a breach likely to affect to a significant degree the safet y 
and ri ghts of  a parti cipant or the reliabilit y and robustness o f the data generated in the 
clinical study .
If any (potenti al) seri ous breach occurs in the course of the study , investi gators or other 
site personnel will inform the appropriate AstraZeneca representatives immediately after 
he or she beco mes aware of it.
In certain regions/countries, AstraZeneca has a leg al responsibilit y to notify both the local 
regul atory  authori ty and other regul atory  agencies about such breaches.
AstraZeneca will comply wit h country -specific regulatory  requi rements rel ating to 
serious breach reporting to the regulatory  authori ty, IRB, and investigators. If EU 
Clinical Trials Regulat ion 536/2014 applies, AstraZeneca is required to enter details 
of serious breaches into the European Medicines Agency Clinical Trial Informat ion 
System . It is important to note that redacted versions o f serious breach reports will be 
available to the public via Clinical Trial Informat ion System .
The invest igator should have a process in place to ensure that:
oThe site staff or service providers delegated by the investigator/inst itution are 
able to ident ify the occurrence of a (potential) serious breach
A (potential) serious breach is pro mptly reported to AstraZeneca or delegated party, 
through the contacts (email address or telephone number) provided by AstraZeneca.
A 2 Financial Disclosure
Invest igators and sub -investigators will provide AstraZeneca with sufficient, accurate 
financial information as requested to allow AstraZeneca to submit complete and accurate 
financial certificat ion or disclosure statements to the appropriate regulatory  authori ties. 
Invest igators are responsible for providing information on financial interests during the study 
and for 1 y ear after com pletion of  the study .
Clinical Study Pro tocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 61of 78 Doc ID: TMP -0010225
Template Version Number 7.0A 3 Informed Consent Process
The invest igator or their representative will explain the nature of the study to the 
participant or the ir legally  authori sed representative and answer all questions regarding 
the study .
Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary, and they  are f ree to 
refuse to participate and may wit hdraw their consent at any  time and for any  reason
during the study . Partici pants or thei r legally  authori sed representative will be required to 
sign a statem ent of  inform ed consent that meets the requirements of 21 CFR 50, local 
regul ations, ICH guidelines, privacy and data protection requirements, where applicable, 
and the IRB or study  centre.
The m edical  record m ust include a statem ent that wri tten inform ed consent was obtained 
before the participant was enrolled in the study  and the date the written consent was 
obtained. The authorised person obtaining the inform ed consent must also sign the ICF.
If new informat ion requires changes to the ICF, consider if participants must be 
re-consented and if so, this must be to the most current version o f the ICF(s) during their 
participat ion in the study.
A copy  ofthe ICF(s) m ust be provi ded to the participant or the participant’s legally  
authori sed representative.
Parti cipants who are rescreened are required to sign a new ICF .
A 4 Data Protection
Parti cipants will be assigned a unique ident ifier by AstraZeneca. Any participant records 
or datasets that are transferred to AstraZeneca will contain the ident ifier only; part icipant 
names or any  information which would make the participant ident ifiable will not be 
transferred.
The parti cipant must be inform ed that thei r personal  study -related data will  be used by  
AstraZeneca in accordance wit h local data protection law. The level of disclo sure and use 
of their data m ust al so be explained to the participant in the informed consent. 
The parti cipant must be inform ed that thei r medical  records m ay be examined by Clinical 
Qualit y Assurance auditors or other authorised personnel appo inted by  AstraZeneca, by  
appropriate IRB members, and by inspectors from regulatory authorities.
The parti cipant must be inform ed that data will be c ollected only  for the business needs. 
We will only co llect and use the minimum amount of personal data to support our 
business act ivities and will not make personal data available to any one (including internal 
staff) who is not authorised or does not have a business need to know the informat ion. 
The parti cipant must be inform ed that in som e cases their data may be pseudonymised. 
The General data Protection Regulat ion defines pseudonymisation as the processing o f 
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 62of 78 Doc ID: TMP -0010225
Template Version Number 7.0personal data in such a way  that the persona l data can no longer be attributed to a specific 
individual wit hout the use of addit ional informat ion, provi ded that such addit ional 
inform ation is kept separately and protected by  technical and organisational measures to 
ensure that the personal data are not attributed to an identified or ident ifiable natural 
person.
A 5 Committees Structure
Not applicable. 
A 6 Dissemination of Clinical Study Data
Any results both technical and lay  summaries for this trial, will be submitted to EU CTIS 
within a year from  global E nd of Trial Date in all participat ing countries, due to scient ific 
reasons, as otherwise statistical analysis is not relevant.
A descri ption of this clinical study  will be available on 
http://astrazenecagrouptrials.pharmacm.com and http://www .clinicaltrial s.gov as will the 
summary of the mainstudy  resul ts when they  are available. The clinical study  and/or 
summary of main study  resul ts may also be available on other websites according to the 
regul ations of the countries in which the mainstudy  is conducted.
A 7 Data Quality Assurance
All participant data relat ing to the study  will be recorded on eCRF unless transmitted to 
AstraZeneca or designee electronically  (eg, l aboratory  data). The invest igator is 
responsible for verifying that data entries are accurate and correct by  electroni cally 
signing the eCRF.
The invest igator must maintain accurate documentation (source data) that supports the 
inform ation entered in the eCRF.
The invest igator must permit study -related m onitoring, audi ts, IRB revi ew, and regulatory  
agency inspect ions and provide direct access to source data documents.
Moni toring details describing strategy , including definit ion of study -critical data i tems 
and processes (eg, risk -based init iatives in operations and qualit y such as Risk 
Management and M itigation Strategies and Analyt ical Risk -based Monitoring), methods, 
responsibilit ies and requirements, including handling of nonco mpliance issues and 
monitoring techniques (central, remote, or on -site monitoring) are included in the 
Moni toring Pl an.
AstraZeneca or designee is responsible for medical oversight throughout the conduct of 
the study  which includes clinical reviews of study  data in accordance with the current ly 
approved protocol. Monitoring details describing clinical reviews of study  data from a 
medical perspect ive are included in more detail in the Moni toring Plan .
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 63of 78 Doc ID: TMP -0010225
Template Version Number 7.0AstraZeneca or designee is responsible for the data management of this study , including 
qualit y checking of the data.
AstraZeneca assumes accountabilit y for acti ons delegated to other individuals (eg, 
CROs).
Study  monitors will perform  ongoing source data verification as per the 
Moni toring Plan(s) to confirm that data entered into the eCRF by authorised site 
personnel are accurate, complete, and verifiable from source documents; that the safet y 
and ri ghts of  parti cipants are being protected; and that the study  is being conducted in 
accordance with the current ly approved protocol and any other study agreements, ICH 
GCP, and all applicable regulatory  requi rements.
Records and docume nts, including signed ICFs, pertaining to the conduct of this study  
must be retained by the invest igator for a minimum o f 25 years after study  archiving or as 
requi red by l ocal regulat ions, according to the AstraZeneca Glo bal Retent ion and 
Disposal  (GRAD) schedule. No records may be destroy ed during the retention period 
without the wri tten approval  of AstraZeneca. No records may be transferred to another 
location or party  without wri tten notificat ion to AstraZeneca.
A 8 Source Documents
Source documents provide evidence for the existence of the participant and substantiate 
the integrit y of the data collected. Source documents are filed at the invest igator’s site.
Data entered in the eCRF that are transcribed from source documents must be consistent 
with the sour ce documents or the discrepancies must be explained. The investigator may 
need to request previous medical records or transfer records, depending on the study. 
Also, current medical records must be available.
Definit ion of what constitutes source data and its origin can be found in Source Data 
Ident ification Form provided by Labcorp .
A 9 Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruit ment of 
participants.
The first act of recruitment is the first site open and will be the study  start date.
AstraZeneca designee reserves the right to close the study  site or terminate the study  at any  
time for any  reason at the sole discret ion of AstraZeneca. Study sites will be closed upon study 
completion. A study site is considered cl osed when all  requi red docum ents and study  supplies 
have been co llected and a study -site closure visi t has been perform ed.
The invest igator may init iate study -site closure at any  time, provi ded there i s reasonable cause 
and suffic ient noti ce is given in advance of the intended terminat ion.
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 64of 78 Doc ID: TMP -0010225
Template Version Number 7.0Reasons for the early closure of a study  site by AstraZeneca or the invest igator may include 
but are not limited to:
Failure of the invest igator to comply wit h the protocol, the requirements of t he IRB or 
local heal th authori ties, AstraZeneca’s procedures, or GCP guidelines
Inadequate recruit ment of parti cipants by  the investi gator
Discontinuati on of  further study  intervent ion developm ent
If the study  is prem aturely  terminated or suspended, Astra Zeneca shall pro mptly inform  the 
investigators, the IRBs, the regulatory  authori ties, and any  CRO(s) used in the study  of the 
reason for terminat ion or suspensio n, as specified by the applicable regulatory  requi rements. 
The invest igator shall prompt ly inform the parti cipant and shoul d assure appropriate 
participant therapy  and/or follow -up.
A 10 Publication Policy
The results of this study  may be published or presented at scient ific meet ings. If this is 
foreseen, the invest igator agrees to submit all manuscripts or abstracts to AstraZeneca 
before submissio n. This allows AstraZeneca to protect proprietary  inform ation and to 
provi de comments.
AstraZeneca will comply wit h the requirements for publicat ion of study  resul ts. In 
accordance with standard editorial and et hical practice, AstraZeneca will generally 
support publication o f multicentre studies only in their ent irety and not as individual site 
data. In this case, a coordinat ing investigator will be designated by mutual agreement.
Authorship will be determined by mutual  agreement and in line wit h Internat ional 
Committee of Medical Journal Editors authorship requirements.
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 65of 78 Doc ID: TMP -0010225
Template Version Number 7.0Appendix BAEs: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
B 1 Definition of AEs
An AE is the devel opment of any untoward m edical  occurrence in a patient or clinical study 
participant administered a medicinal product, and which does not necessarily have a causal 
relationship with this treatment. An AE can therefore be any unfavourable and unintended sign 
(eg, an abnormal laboratory  finding), symptom (for examp le nausea, chest pain), or disease 
temporally  associ ated wi th the use of a m edicinal product, whether it’ s considered related to 
the medicinal product. 
The term  AE is used to include both serious and non -serious AEs and can include a 
deteri oration of  a pre-exist ing medical occurrence. An AE may occur at any  time, including 
run-in or washout periods, even if no study  intervent ion has been administered.
B 2 Definition of SAEs
An SAE is an AE occurring during any  study  phase (i e, run -in, treatment, washout, 
follow-up), that fulfils one or more of the following criteria:
Results in death.
Is immediately life -threatening.
Requi res in -patient hospi talisat ion or prolongat ion of exist ing hospi talisat ion. 
Results in persistent or significant disabilit y or incapaci ty. 
Is a congenital ano maly or bi rth defect.
Is an important medical event that may jeopardise the participant or may require medical 
treatm ent to prevent one of the outcomes listed above.
Adverse Events for malignant tumours reported during a study  shoul d generally be assessed 
as SAEs . If no other seri ousness criteria apply , the ‘Important Medi cal Event ’ criterion shoul d 
be used. In certain situat ions, however, medical judgement on an individual event basis should 
be applied to clarify that the m alignant tum our event shoul d be assessed and reported as a 
non-SAE . For example, if the tumour is included as medical history  and progression occurs 
during the study , but the progression does not change treatment and/or prognosis of th e 
malignant tumour, the AE m ay not fulfil the attributes for being assessed as serious, although 
reporting of the progression of the malignant tumour as an AE is valid and should occur .Also, 
some ty pes of  malignant tum ours, which do not spread remotely af ter a routine treatment that 
does not require hospitalisat ion, may be assessed as non -serious; examples in adult s include 
Stage 1 basal cell carcino ma and S tage 1A1 cervical cancer removed via cone biopsy .
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 66of 78 Doc ID: TMP -0010225
Template Version Number 7.0Life-threatening
‘Life-threatening ’ means that the participant was at immediate risk of death fro m the AE as i t 
occurred, or it is suspected that use or continued use of the medicinal product would result in 
the participant ’s death. ‘Life-threatening ’ does not mean that had an AE occurred in a more 
severe form it might have caused death (eg, hepatitis that resolved without hepat ic failure).
Hospitalisation
Outpati ent treatm ent in an emergency room is not in itself a SAE, although the reasons for it 
may be (eg, bronchospasm, laryngeal oedema). Hospital admi ssions and/or surgical operations 
planned before or during a study  are not consi dered AEs if the illness or disease existed before 
the participant was enro lled in the study , provi ded that i t did not deteriorate in an unexpected 
way during the study .
Import ant Medical Event or Medical Treatment
Medical and scientific judgement should be exercised in deciding whether a case is serious in 
situations where important m edical events may  not be immediately life threatening or result in 
death, hospi talisat ion, disability or incapaci ty but may jeopardise the participant or may  
requi re medical treatm ent to prevent one or more outcomes listed in the definit ion of seri ous. 
These should usually be considered as serious.
Simply stopping the suspect drug does not mean that it is an important medical event; medical 
judgement must be used.
Examples include:
Angioedema not severe enough to require intubation but requiring intravenous 
hydrocortisone treatment
Hepatotoxicit y caused by paracetamo l (acetaminophen) overdose requiri ng treatm ent 
with N-acetylcysteine
Intensive treatment in an emergency room or at home for allergic bronchospasm
Blood dy scrasias (eg, neutropenia or anaemia requiring blood transfusion, etc .) or 
convulsio ns that do not result in hospitalisat ion
Development of drug dependency or drug abuse
Intensity Rating Scale
Mild (awareness of sign or symptom, but easily tolerated)
Moderate (di scomfort sufficient to cause interference with normal act ivities)
Severe (incapacitat ing, with inabilit y to perform  normal activities)
It is important to dist inguish between serious and severe AEs. Severit y is a measure of 
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 67of 78 Doc ID: TMP -0010225
Template Version Number 7.0intensity whereas seri ousness is defined by the criteria in Appendix B 2. An AE of severe 
intensity need not necessarily be considered serious. For example, nausea that persists for 
several hours may  be consi dered severe nausea, but not an SAE unless it meets the criteria 
shown in
 Appendix B 2. On the other hand, a stroke that results in only a limited degree of 
disabili ty may be considered a mild stroke but would be an SAE when it satisfies the criteria 
shown in 
Appendix B 2.
B3 A Guide to Interpreting the Causality Question
When assessing causalit y consider the fo llowing factors when deci ding if there is a 
‘reasonable possibilit y
’that an AE may have been caused by the medicinal product.
Time course. Exposure to suspect drug. Has the participant received the suspect drug? 
Did the AE occur in a reasonable temporal relat ionship to the admini strati on of  the 
suspect drug?
Consistency wit h known drug profile. Was the AE consistent with the previous 
knowl edge of the suspect drug (pharmaco logy and toxi cology) or drugs of the same 
pharmaco logical class? Or could the AE be ant icipated from its pharm acological 
properties?
De-challenge experience. Did the AE resolve or improve on stopping or reducing the dose 
of the suspect drug?
No al ternative cause. The AE cannot be reasonably explained by another aetio logy such 
as the underlying disease, other drugs, other host, or environmental factors.
Re-challenge experi ence. Di d the AE reoccur if the suspected drug was reintroduced after 
having been stopped? AstraZeneca would not normally reco mmend or support a 
re-challenge .
Laboratory  tests. A specific labo ratory  invest igation (if performed) has confirmed the 
relationship .
In difficult cases, other factors could be considered such as:
Is this a recogni sedfeature of overdose of the drug?
Is there a known mechanism?
Causalit y of ‘related ’ is made if fo llowi ng a review of the relevant data, there is evidence for a 
‘reasonable possibilit y’of a causal relationship for the individual case. The expression 
‘reasonable possibilit y’ of acausal  relati onship is meant to convey , in general ,that there are 
facts (evidence) or arguments to suggest a causal relat ionship .
The causalit y assessment i s perform ed based on the available data including enough 
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 68of 78 Doc ID: TMP -0010225
Template Version Number 7.0inform ation to m ake an informed judgment. W ith no available facts or arguments to suggest a 
causal relat ionship, the eve nt(s) will be assessed as ‘not rel ated’.
Causal relat ionship in cases where the disease under study  has deteri orated due to l ack of 
effect shoul d be classified as ‘no reasonable possibilit y’.
B 4 Medication Error, Drug Abuse, and Drug Misuse
Medication Error
For the purposes of this clinical study  a medicat ion error is an unintended failure or mistake in 
the treatment process for an IMP or AstraZeneca NIMP that either causes harm to the 
participant or has the potential to cause harm to the participant. 
A medicat ion error is not lack of efficacy of the drug, but rather a human or process related 
failure while the drug is in control of the study  site staf f or parti cipant.
Medicat ion error includes situat ions where an error: 
Occurred
Was identified and intercepte d before the participant received the drug
Did not occur, but circumstances were recognised that could have led to an error
Examples of events to be reported in clinical studies as medication errors:
Drug name confusio n
Dispensing error, eg, medicat ion prepared incorrectly, even if it was not actually given to 
the participant
Drug not administered as indicated, eg, wrong route or wrong site of administration
Drug not taken as indicated, eg, tablet disso lved in water when it should be taken as a 
solid table t 
Drug not stored as instructed, eg, kept in the refrigerators when it should be at room 
temperature 
Wrong participant received the medicat ion (excluding IRT/RTSM errors)
Wrong drug administered to participant (excluding IRT/RTSM errors)
Examples of events that do not require reporting as medicat ion errors in clinical studies:
Errors related to or resulting fro m IRT/RTSM -including those which led to one of the 
above listed events that would otherwise have been a medication error 
Parti cipant acci dentally  missed drug dose(s), eg, forgot to take medication
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 69of 78 Doc ID: TMP -0010225
Template Version Number 7.0Accidental  overdose (will be captured as an overdose)
Parti cipant f ailed to return unused medicat ion or empt y packaging
Medicat ion errors are not regarded as AEs but AEs may occur as a c onsequence of the 
medicat ion error .
Drug Abuse
For the purpose of this study , drug abuse is defined as the persistent or sporadic intent ional, 
non-therapeut ic excessive use of IMP or AstraZeneca NIMP for a perceived reward or desired 
non-therapeut ic effec t.
Any events of drug abuse, with or without associated AEs, are to be captured and forwarded to 
the data entry  site using the Drug Abuse Report Form . This form should be used both if the 
drug abuse happened in a study  parti cipant or if the drug abuse invo lves a person not enrolled 
in the study  (such as a rel ative of the study  parti cipant).
Examples of drug abuse include but are not limited to:
The drug is used with the intent of getting a perceived reward (by the study  parti cipant 
or a person not enrolled in the study )
The drug in the form o f a tabl et is crushed and injected or snorted with the intent of 
getting high
Drug Misuse
Drug misuse is the intent ional and inappropriate use (by  a study parti cipant) of IMP or 
AstraZeneca NIMP for medicinal purposes o utside of the authori sed product informat ion, or 
for unauthorised IMPs or AstraZeneca NIMPs, outside the intended use as specified in the 
protocol  and includes deliberate administration of the product by  the wrong route.
Events of drug misuse, with or with out associ ated AEs, are to be captured and forwarded to 
the data entry  site using the Drug Misuse Report Form. This form should be used both if the 
drug misuse happened in a study  parti cipant or if the drug misuse regards a person not 
enrolled in the study (such as a relative of the study participant).
Examples of drug misuse include but are not limited to:
The drug is used with the intent ion to cause an effect in another person
The drug is so ld to other people for recreational purposes 
The drug is used to facilitate assault in another person
The drug is deliberately administered by the wrong route
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985 C00007
CONFIDENTIAL AND PROPRIETARY 70of 78 Doc ID: TMP -0010225
Template Version Number 7.0The drug is split in half because it is easier to swallow, when it is stated in the protocol 
that it must be swallowed whole
Only half the dose is taken because the study  partici pant feels that he/she is feeling 
better when not taking the whole dose
Someone who i s not enrolled in the study  intentionally  takes the drug
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 71of 78 Doc ID: TMP -0010225
Template Version Number 7.0Appendix CHandling of Human Biological Samples
C 1 Chain of Custody
A full chain of custody  is maintained for all samples throughout their lifecycle.
The invest igator at each centre keeps full traceability of co llected bio logical sam ples f rom the 
participants while in storage at the centre until shipment or disposal (where appropriate) and 
records relevant process ing information related to the samples whilst at the site.
The sample receiver keeps full traceabilit y of the sam ples while in storage and during use unt il 
used or disposed of or until further shipment, and keeps record of receipt of arrival and 
onward shi pment or disposal.
AstraZeneca or delegated representatives will keep oversight of the ent ire life cycle through 
internal  procedures, m onitoring of study  sites, auditing or process checks, and contractual 
requi rements of external laboratory  provi ders
Samples retained for further use will be stored in the AstraZeneca -assigned bi obanks or other 
sample archive facilit ies and will be tracked by  the appropri ate AstraZeneca team for the 
remainder of the sample life cycle.
All appropri ately  consented sam ples will be retained for maximum 15 y ears f rom last subject 
last vi sit.
If required, AstraZeneca will ensure that remaining bio logical samples are returned to the site 
according to local regulations or at the end of the retention period, whichever is the sooner .
C 2 Withdrawal of Informed Consent for Donated Biological Samples 
If a participant withdraws consent to the use of donated bio logical  samples, the sam ples will 
be disposed of/destroy ed/repatriated, and the action documented. If samples are already  
analysed, AstraZeneca is not obliged to destroy the results of this research.
Following wi thdrawal  of consent for bio logical samples, further study  partici pation shoul d be 
considered in relat ion to the wi thdrawal  processes outlined in the informed consent.
The invest igator:
Ensures the participant’s wit hdrawal o f informed consent to the use of donated samples is 
highlighted immediately to AstraZeneca or delegate.
Ensures that relevant HBS fro m that participant, if stored at the study  site, are 
immediately  identified, di sposed of as appropriate, and the action documented.
Ensures that the participant and AstraZeneca are informed about the sample disposal.
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 72of 78 Doc ID: TMP -0010225
Template Version Number 7.0AstraZeneca ensures the organisation(s) holding the samples is/are informed about the 
withdrawn consent immediately a nd that sam ples are disposed of or repatriated as appropriate, 
and the action is documented, and study  site is notified.
C 3 International Air Transport Association Guidance Document 62nd
edition
LABELLING AND SHIPMENT OF BIOHAZARD SAMPLES
The Internat ional Ai r Transport Associat ion (IATA) 
(https://www .iata.org/whatwedo/cargo/dgr/Pages/download.aspx ) classifies infect ious 
substances into 3 categories: Category  A, Category B, or Exempt
Category A Infectious Substances are infect ious substances in a form that, when exposure to 
it occurs, i s capable of causing permanent disabilit y, life-threatening or fatal disease in 
otherwi se healt hy humans or animals. 
Category A Pathogens are, eg, Ebola, Lassa fever virus. Infect ious substances meet ing these 
criteria which cause disease in humans or both in humans and animals must be assigned to 
UN2814. Infect ious substances which cause disease only in animals must be assigned to 
UN2900.
Category B Infectious Substances are infect ious substances that do not meet the criteria for 
inclusio n in Category  A. Category  B pathogens are, eg, Hepatitis A, C, D, and E viruses. They 
are assigned the fo llowing UN number and proper shipping name:
UN 3373 –Biological Substance, Category  B
Are to be packed in accordance with UN 3373 and IATA 650
Exempt Substances are substances which do not contain infect ious substances, or substances 
which are unlikely to cause disease in humans or animals, are not subject to these regulat ions 
unless they  meet the cri teria for inclusi on in another class.
Clinical study  samples wi ll fall into Category  B or exempt under IATA regulat ions.
Clinical study  samples will routinely  be packed and transported at ambient temperature in 
IATA 650 compliant packaging 
(https://www.iata.org/contentassets/b08040a138dc4442a4f066e6fb99fe2a/dgr -
62-en-
pi650.pdf).
Biological samples transported in dry  ice requi re addi tional dangerous goods specificat ion 
for the dry -ice content.
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 73of 78 Doc ID: TMP -0010225
Template Version Number 7.0Appendix DMedical Device AEs, ADEs, SAEs, SADEs, USADEs, and 
Medical Device Deficiencies: Definitions and Procedures 
for Recording, Evalua ting, Follow -up, and Reporting
The definit ions and procedures detailed in this appendix are in accordance wit h 
International Organizat ion for Standardizat ion 14155 and European Medical Device 
Regulation 2017/745 for clinical device research (if applicable) . 
Both the invest igator and AstraZeneca will co mply wi th all local reporting requi rements 
for medical devices.
The detecti on and docum entati on procedures described in this protocol apply  to all  
sponsor combinat ion products provided for use in the study . See Secti on 6.1.1 for the list 
of sponsor combinat ion products .
D 1 Definition of Medical Device AE and ADE
Medical Device AE and ADE Definition
A medical device AE is any untoward medical occurrence in a clinical study  participant, 
users, or other persons, temporally associated with the use of study  intervent ion, whether 
or not considered related to the medical device. An AE can therefore be any unfavourabl e 
and unintended sign (including an abnormal laboratory  finding), symptom, or disease 
(new or exacerbated) temporally associated with the use of a medical device. This 
definit ion includes events related to the medical device or comparator and events relate d 
to the procedures invo lved except for events in users or other persons, which only include 
events related to medical devices.
ADE is defined as an AE related to the use of a medical device. This definit ion includes 
any AE result ing from insuffic ient or i nadequate instructions for use, deplo yment, 
implantati on, installat ion, or operation, or any  malfunct ion of the medical device as well 
as any event result ing from use error or from intentio nal misuse of the medical device.
D 2 Definition of Medical Device SAE, SADE, and USADE
A Medical Device SAE is an any AE that:
a.Led to death.
b.Led to serious deterioration in the healt h of the participant, that either resulted in:
A life-threatening illness or injury. The term ‘life -threatening’ in the definit ion of 
‘serious’ refers to an event in which the participant was at risk of death at the time of the 
event. It does not refer to an event, which hypothetically might have caused death if it 
were m ore severe.
A permanent impairment of a body  structure or a body  function.
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 74of 78 Doc ID: TMP -0010225
Template Version Number 7.0Inpatient or prolonged hospitalisat ion. Planned hospi talisat ion for a pre -exist ing 
condi tion, or a procedure required by the protocol, without serious deterioration in healt h, 
is not considered an SAE.
Medical or surgical intervent ion to prevent life -threate ning illness or injury or permanent 
impairment to a body  structure or a body  function.
Chronic disease (European Medical Device Regulation 2017/745).
c.Led to foetal distress, foetal death, or a congenital ano maly or bi rth defect.
A Medical Device SADE is:
Any ADE that has resulted in any  of the consequences characterist ic of an SAE.
Any medical device deficiency that might have led to an SAE if appropriate action had 
not been taken, intervent ion had not occurred, or circumstances had been less fortunate.
USA DE Definition:
A USADE (also ident ified as UADE in the US Regul ation 21 CFR 812.3) is defined as a 
SADE that by  its nature, incidence, severit y, or outcom e has not been i dentified in the 
current version of the risk analysis report (see Sectio n 2.3).
D 3 Definition of Medical Device Deficiency
Medical Device Deficiency Definition
A device deficiency  is an inadequacy of a medical device wit h resp ect to i ts identi ty, 
qualit y, durabilit y, reliabilit y, safet y, or perform ance. Device deficiencies include 
malfunct ions, use errors, and inadequacy of the information supplied by the manufacturer.
D 4 Recording and Follow -up of Medical Device AE and/or SAE and
Medical Device Deficiencies
AE, SAE, and Medical Device Deficiency Recording
When an AE/SAE/medical device deficiency occurs, it is the responsibilit y of the 
investigator to review all documentation (eg, hospital progress notes, laboratory  reports, 
and diagnosti cs reports) rel ated to the event.
The invest igator will then record all relevant AE/SAE/medical device deficiency 
inform ation in the participant’s medical records, in accordance with the invest igator’s 
norm al clinical pract ice and on the appropria te form.
It is notacceptable for the invest igator to send photocopies of the participant’s medical 
records to sponsor or designated CRO in lieu of complet ion of the AE/SAE/medical 
device deficiency form.
There m ay be instances when copies of medical recor ds for certain cases are requested by 
the sponsor . In this case, all participant ident ifiers, except for the participant number, will 
be redacted on the copies of the medical records before submissio n to the sponsor .
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 75of 78 Doc ID: TMP -0010225
Template Version Number 7.0The invest igator will attempt to establ ish a diagnosis of the event based on signs, 
symptoms, and/or other clinical informat ion. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
For m edical device deficiencies, it is very  important that the invest igator describes any 
corrective or remedial act ions taken to prevent recurrence of the deficiency.
oA remedial act ion is any action other than routine maintenance or servicing o f a 
medical device where such act ion is necessary  to prevent recurrence of a medical 
device deficiency. This includes any protocol revisio n to the medical device design to 
prevent recurrence.
Assessment of Intensity
The invest igator will assess intensit y for each AE/SAE/m edical  device deficiency reported 
during the study  and ass ign it to one of the following categories: 
Mild (awareness of sign or symptom, but easily tolerated)
Moderate (di scomfort sufficient to cause interference with normal act ivities)
Severe (incapacitat ing, with inabilit y to perform  norm al activities)
Other m easures to eval uate AEs and SAEs may be used (eg, National Cancer Inst itute 
Commo n Termino logy Cri teria for Adverse Events).
Assessment of Causality
The invest igator is obligated to assess the causal relat ionship between study  intervent ion 
and each occurre nce of AE/SAE/medical device deficiency.
A ‘reasonable possibilit y’ of a relationship conveys that there are facts, evidence, and/or 
argum ents to suggest a causal relationship.
The invest igator will use clinical judgment to determine the relat ionship.
Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study  intervent ion 
administration will be considered and invest igated.
The invest igator will also consult the IB and/or Investigational Direct ions for Use (IDFU) 
or Product Informat ion, for m arketed products in their assessment.
For each AE/SAE/medical device deficiency , the investi gator must document in the 
medical notes that they  have reviewed the AE/SAE/medical device deficiency and have 
provi ded an assessment of causalit y.
There m ay be si tuations in which an SAE has occurred, and the invest igator has minimal 
inform ation to include in the i nitial report to the sponsor. However, it is very  important 
that the investigator always make an assessment of causalit y for every  event before the 
initial transmissio n of the SAE data to the sponsor.
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 76of 78 Doc ID: TMP -0010225
Template Version Number 7.0The invest igator may change their opinio n of causalit y in light of fo llow-up inform ation 
and send an SAE fo llow-up report wi th the updated causalit y assessment.
The causalit y assessment is one of the cri teria used when determining regulatory  
reporting requirements.
Causalit y of ‘related’ is m ade if fo llowing a review of the relevant data, there is evidence for a 
‘reasonable possibilit y’ of a causal relationship for the individual case. The expressio n 
‘reasonable possibilit y’ of a causal relationship is meant to convey, in general, that there are 
facts (evidence ) or argum ents to suggest a causal relat ionship.
The causalit y assessment i s perform ed based on the available data including enough 
inform ation to m ake an informed judgment. With no available facts or arguments to suggest a 
causal relat ionship, the event(s ) will be assessed as ‘not related’.
Follow -up of AE/SAE/Medical Device Deficiency
The invest igator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested by the sponsor to 
elucidate the nature and/or causalit y of the AE/SAE/medical device deficiency as fully as 
possible. This may include addit ional laboratory  tests or invest igations, histopathological 
examinat ions, or consultation with other health care professio nals.
Ifa parti cipant di es during participation in the study  or during a recognised follow -up 
period, the invest igator will provide the sponsor with a copy of any post -mortem findings 
including histopathology .
New or updated informat ion will be recorded in the or iginal form  used to report the 
deficiency.
The invest igator will submit any updated SAE data to the sponsor within 24 hours of 
recei pt of the inform ation.
D 5 Reporting of Medical Device SAEs and SADEs
All medical device SAEs will be reported in accordance wit h Section 7.4.7 .
NOTE: There are addit ional reporting obligat ions for SADEs that must fulfil the legal 
responsibilit y to notify appropriate regulator y authori ties and other entit ies about certain 
safet y informat ion relating to medical devices being used in clinical studies.
Any medical device deficiency that is associated wit h an SAE must be reported to 
AstraZeneca within 24 hours after the invest igato r determines that the event meets the 
definit ion of a medical device deficiency .
In addit ion to the reporting process described in Section 7.4.7 , the AstraZeneca Clinical 
Study  Medical Device/Device Const ituent Report Form will be used to capture details o f 
the device and related deficiency.
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 77of 78 Doc ID: TMP -0010225
Template Version Number 7.0Facsimile transmissio n of the AstraZeneca Clinical Study  Medical  Device/Device 
Const ituent Report Form is the preferred method to transmit this informat ion to the Study  
Clinical Lead/SAE coordinator.
In rare circumstances and in the absence of facsimile equipment, notificat ion by telephone 
is acceptable with a copy  of the AstraZeneca Clinical Study  Medical  Device/ Device 
Const ituent Report Form sent by overnight mail or courier service.
Initial notificati on via telephone does not replace the need for the invest igator to complete 
and sign the AstraZeneca Clinical Study  Medical Device/Device Const ituent Report Form 
within the designated reporting t ime frames.
AstraZeneca will review all medical device deficiencies and determine and document in 
writing whether they  coul d have l ed to an SAE. These medical device deficiencies will be 
reported to the regulatory  authori tiesand IRBs as required by nat ional regulat ions.
Contacts for SAE reporting can be found in the Safety  Handling Pl an.
Clinical Study Protocol -1.0 AstraZeneca
Breztri PT010 -D5985C00007
CONFIDENTIAL AND PROPRIETARY 78of 78 Doc ID: TMP -0010225
Template Version Number 7.010 REFERENCES
Buhl R, T anase AM, Hosoe M, Cao W , Demin I, Bartels C, et al. A randomized, doubl e-blind 
study  to com pare the efficacy and safet y of two doses of mo metasone furoate delivered via 
Breezhaler®or Twisthaler®in pat ients with asthma. Pulm Pharmaco l Ther . 2020;62:101919.
Global Init iative for Asthma (GINA). Global Strategy  for Asthma Management and 
Prevent ion, 2022. http://ginasthma.or g.
Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. 
Standardi zation of Spiro metry 2019 Update. An Official American Thoracic Societ y and 
European Respiratory  Soci ety Technical Statement. Am J Respir Crit Care Med. 2019 Oct
15;200(8):e70 -e88.
Invest igator ’s Brochure -Budesonide, Glycopyrronium and Formoterol Fumarate Inhalat ion 
Aerosol (BGF MDI); Budesonide and Formoterol Fumarate Inhalat ion Aerosol (BFF MDI); 
Budesonide Inhalat ion Aerosol (BD MDI); Glycopyrronium Inhalat ion Aerosol (GP MDI) 
(Also known as PT010 [BGF MDI], PT009 [BFF MDI], PT008 (BD MDI); PT001 (GP MDI); 
Edition Number 9.0, 16 September 2022.
Juniper EF , Bousquet J, Abetz L, Bateman ED. Ident ifying ‘well-controlled ’ and ‘not 
well-controlled ’ asthma using the Asthma Control Quest ionnaire. Resp Med. 2006 
Apr;100:616 -
21.
Juniper EF , O’Byrne PM, Guy att GH, Ferri e PJ, King DR. Development and validat ion of a 
questionnaire to measure asthma control. Eur Respir J. 1999a;14(4):902-7.
Miller MR, Hankinson J, Brusasco V, Burgos F , Casaburi  R, Coates A, et al. Standardisat ion 
of spirometry. Eur Respi r J. 2005;26(2):319 -38.
Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al; ERS Global Lung 
Funct ion Init iative. Mult i-ethnic reference values for spiro metry for the 3 -95-yr age range: the 
global lung f uncti on 2012 equat ions. Eur Respir J. 2012 Dec;40(6):1324 -
43.
Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung vo lumes 
and forced vent ilatory flo ws. Report Working Party Standardizat ion of Lung Funct ion Tests, 
European Communit y for Steel  and Coal . Official Statem ent of the European Respiratory  
Society. Eur Respi r J. 1993;6: Suppl. 16 S5 –S40.
SIGNATURE PAGE
This is a representation of an electronic record that was signed
electronically and this page is the manifestation of the electronic signature
Document Name: d5985c00007-csp-v1
Document Title: D5985C00007 Clinical Study Protocol version 1
Document ID: Doc ID-004953675
Version Label: 1.0 CURRENT LATEST APPROVED
Server Date
(dd-MMM-yyyy HH:mm ‘UTC’Z)Signed by Meaning of Signature
22-Dec-2022 16:38 UTC Content Approval
24-Dec-2022 00:48 UTC Author Approval
27-Dec-2022 10:55 UTC Content Approval
22-Dec-2022 16:43 UTC Content Approval
Notes: (1) Document details as stored in ANGEL, an AstraZeneca document management system.PPD
PPD
PPD
PPD